

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
23 October 2003 (23.10.2003)

PCT

(10) International Publication Number  
WO 03/087347 A1

(51) International Patent Classification<sup>2</sup>: C12N 5/00, 5/02,  
G01N 33/53, A61K 45/00, 47/00, A01N 63/00, 65/00

(21) International Application Number: PCT/US02/11319

(22) International Filing Date: 12 April 2002 (12.04.2002)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (for all designated States except US): MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. [US/US]; 1120 15th Street, Augusta, GA 30912-4810 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MELLOR, Andrew [GB/US]; 480 Falcon Drive, Martinez, GA 30907 (US). MUNN, David [US/US]; 967 Meigs Street, Augusta, GA 30904 (US).

(74) Agents: CALKINS, Charles et al.; Kilpatrick Stockton LLP, 1001 West Fourth Street, Winston-Salem, NC 27101 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 03/087347 A1

(54) Title: ANTIGEN-PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS FOR ENHANCING OR REDUCING IMMUNE TOLERANCE

(57) Abstract: The present invention is based on the discovery antigen-presenting cells (APCs) may be generated to have predetermined levels of expression of the intracellular enzyme, indoleamine 2,3-dioxygenase (IDO). Because expression of high levels of IDO is correlated with a reduced ability to stimulate T cell responses and an enhanced ability to induce immunologic tolerance, APCs having high levels of IDO may be used to increase tolerance in the immune system, as for example in transplant therapy or treatment of autoimmune disorders. For example, APCs having high levels of IDO, and expressing or loaded with at least one antigen from a donor tissue may be used to increase tolerance of the recipient to the donor's tissue. Alternatively, APCs having reduced levels of IDO expression and expressing or loaded with at least one antigen from a cancer or infectious pathogen may be used as vaccines to promote T cell responses and increase immunity.

**ANTIGEN-PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS  
FOR ENHANCING OR REDUCING IMMUNE TOLERANCE**

5 The studies described herein were supported at least in part by Federal grants from the  
National Institutes of Health (NIH R01 HL60137; NIH R01 HL57930; NIH R01 AI44219;  
NIH R21 AI49849; NIH R21 AI44759; and NIH K08 HL03395), the National Institutes of  
Health and National Cancer Institute (NIH/NCI/RAID) and the Mason Trust Foundation.  
Thus, the Federal government may have rights in this invention.

10 **FIELD OF THE INVENTION**

15 The invention relates to the use of cell-based pharmaceuticals, and more specifically,  
to the use of antigen-presenting cells (APCs) selected as comprising immunosuppressive  
APCs for inducing tolerance, or immunostimulatory APCs for inducing an increased immune  
response. As examples, immunosuppressive APCs may be used as transplant therapeutics,  
whereas preparations of immunostimulatory APCs may be used as anti-cancer or anti-viral  
vaccines.

**BACKGROUND OF THE INVENTION**

20 Once established, human tumors are not rejected by the immune system, a state of  
functional tolerance which eventually proves fatal to the host (Smyth, M.J., *et al.*, *Nat. Immunol.* **2**, 293 (2001)). Evidence from murine models suggests that immunologic  
unresponsiveness may arise when tumor-associated antigens are presented by certain bone  
marrow-derived tolerogenic (tolerance-producing) antigen-presenting cells (APCs)  
(Sotomayor, E. M., *et al.*, *Blood*, **98**: 1070-1077 (2001); Doan, T., *et al.*, *Cancer Res.*, **60**:  
25 2810-2815 (2000)). In the setting of tissue transplantation, it would be desirable to isolate  
and administer such tolerogenic APCs. However, in humans and other mammals (other than  
mice), the identity of these APCs, and the mechanisms they use to induce tolerance, remain  
elusive.

30 In humans, "immature" myeloid dendritic cells (DCs) have been postulated to  
function as tolerizing APCs based on findings that these cells: (1) have a decreased ability to  
stimulate T cell responses *in vitro* (Reddy, A., *et al.*, *Blood*, **90**: 3640-3646 (1997); Jonuleit,  
H., *et al.*, *Eur. J. Immunol.*, **27**: 3135-3142 (1997)); (2) may promote the function of  
immunosuppressive or "regulatory" T cells following prolonged co-incubation (Jonuleit, H.,  
*et al.*, *Trends Immunol.*, **22**: 394-400 (2001)); and (3) have the ability to abrogate antigen-

specific T cell responses *in vivo* (Dhodapkar, M.V., *et al.*, *J. Exp. Med.*, **193**: 233-238 (2001); see also U.S. Patent Nos. 5,871,728 and 6,224,859). However, the molecular mechanism used by immature DCs or other putative tolerogenic APCs to suppress T cell responses is unclear. Moreover, there is currently no way to identify or isolate tolerogenic APCs *in vitro* or *in vivo*, and thus, their use as therapeutic agents is still not available for most applications.

More fundamentally, the supposition that immature DCs are tolerogenic is based on an unproven and potentially flawed model of how APCs regulate T cell activation. Thus, a prevailing model teaches that T cells are rendered unresponsive (or "tolerized") when they receive an activation signal (signal 1) via the T cell antigen receptor (TCR) without receiving co-stimulatory signals (e.g. from CD80 and CD86) delivered on APCs (signal 2). Immature DCs express low levels of TCR ligands (such as MHC class II antigens) and low levels of the putative costimulatory molecules. Thus, the model teaches that immature DCs are unable to activate T cells because T cells receive signal 1 without adequate signal 2.

Other findings teach against the prevailing model, and indicate that maturation of DCs is not necessarily associated with abrogation of T cell suppression and/or tolerance (Albert, M.L., *Nature Immunol.*, **2**: 1010 (2001); Shortman, K. *et al.*, *Nature Immunol.*, **2**: 988-989 (2001); T. Bankenstein and T. Schuler, *Trends in Immunol.*, **23**: 171-173 (2002)). Instead, there may be a third, as yet undefined signal (signal 3) that acts after T cells have received the signals of antigen presentation and co-stimulation (*i.e.* signals 1 and 2) from a fully mature APC. The third signal then diverts T cells to activation or tolerance. In this model, the tolerogenic phenotype is independent of the maturation status of the APC (in fact, maturation enhances tolerance induction) and depends instead on an intrinsic attribute of the APC (*i.e.* whether it expresses signal 3).

The inventors believe that most DC preparations are in fact mixtures of immunizing (stimulatory) and tolerizing APCs. The presence of a mixed population of DCs in such preparations would explain why therapeutic immunization in cancer patients using DCs remains problematic, with most studies having only limited success (M.A. Morse and H.K. Lyerly, *Curr. Opin. Mol. Ther.*, **2**: 20 (2000)). For example, the preferred source and differentiation status of DCs for clinical use remains controversial (Curiel T.J., and Curiel, D.T., *J. Clin. Invest.*, **109**: 311-312, 2002). Although development of the field has been assisted by the recognition that the maturation state of human DCs plays an important role in their ability to stimulate effective immunity (Dhodapkar, M.V., *et al.*, *J. Clin. Invest.*, **105**: R9-R14 (2000); Dhodapkar, M.V., *et al.*, *J. Exp. Med.*, **193**: 233-238 (2001)), even using the best isolation and maturation strategies and multiple tumor antigens, clinically useful

therapeutic immunization in patients with established tumors has been only partially effective (Banchereau, J., *et al.*, *Cancer Res.*, **61**: 6451-6458 (2001)). Thus, it would be useful to develop methods to isolate DCs which, rather than being a mixed population of activating and suppressive DCs, comprise pure activating DCs.

5 Conversely, these are some situations where increased tolerance to foreign antigens is desired. In one approach, immature dendritic cells (DCs) uncharacterized as suppressive or immunogenic subsets are propagated in the presence of a cytokine regimen to maintain the cells in an immature state. The immature cells are administered to a host in advance of a transplant to enhance tolerance (U.S. Patents Nos. 5,871,728 and 6,224,859). However, this  
10 approach inherently sacrifices efficient antigen presentation and co-stimulation due to the immaturity of the APCs, and risks delivering unwanted immunizing (non-tolerogenic) DCs as part of the heterogeneous DC population. It would be helpful in transplant therapeutics to be able to create well-characterized populations of mature maximally effective tolerogenic APCs which present the antigen subset of interest, but in a tolerizing (tolerance-promoting)  
15 preparation.

What is needed is a way to separate tolerance-inducing APCs from other (non-tolerance-inducing) APCs. The tolerance-inducing APCs can then be used in transplant procedures to promote tolerance to specific donor antigens. The non-tolerance-inducing APCs can be used in conjunction with undesirable foreign antigens (such as tumor antigens)  
20 as a vaccine, to prime the recipient immune system against the antigen in question.

#### SUMMARY OF THE INVENTION

The present invention relies on the discovery that tolerance-inducing (suppressive) antigen-presenting cells (APCs) exhibit high levels of expression of the intracellular enzyme indoleamine-2,3-dioxygenase (IDO), and non-tolerance-inducing (non-suppressive or T-cell activating) APCs exhibit low levels of IDO expression. IDO is both a marker for the suppressive subset, and also the causal mechanism of suppression. Thus, the present invention describes the generation of enriched populations of tolerance-inducing APCs and their use as therapeutics, and the generation of enriched populations of non-suppressive APCs and their use as therapeutics. For example, APCs having high levels of IDO (IDO<sup>H</sup>), and exposed to antigens from a donor may be used to increase tolerance of a transplant recipient to the donor's tissue by presenting the donor's antigens on tolerance-inducing APCs. Conversely, APCs having low levels of IDO (IDO<sup>LO</sup>) may be used to enhance responses to neo-antigens from tumors and infectious agents.

Thus, in one aspect, the present invention comprises a method of making antigen-presenting cells (APCs) for enhancing T cell tolerance comprising the steps of:

- (a) isolating antigen-presenting cells (APCs) or their precursors (APC progenitors) from a first subject; and
- 5 (b) treating the cells to select for tolerance-inducing APCs expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity sufficient to suppress proliferation of T cells (IDO<sup>+</sup> APCs).

In another aspect, the present invention comprises a method for increasing the number of tolerance-inducing antigen-presenting cells (APCs) in a subject comprising treating the 10 subject to increase the production of antigen-presenting cells (APCs) or their precursors (APC progenitors) expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity sufficient to suppress proliferation of T cells (IDO<sup>+</sup> APCs).

In another aspect, the present invention comprises a method for enhancing tolerance in a subject comprising the steps of:

- 15 (a) isolating antigen-presenting cells (APCs) or their precursors (APC progenitors) from a first subject;
- (b) treating the cells to select for tolerance-inducing APCs expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity sufficient to suppress proliferation of T cells (IDO<sup>+</sup> APCs); and
- 20 (c) administering the treated cells of step (b) to the original subject or to a second subject in an amount effective to generate a tolerance-promoting immune response in the recipient subject.

The present invention also provides compositions for enhancing T cell tolerance comprising APCs that express high levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity (IDO<sup>+</sup> APCs). Such tolerizing APCs may be used to promote acceptance of graft or 25 transplant tissue from a donor subject in a recipient. IDO<sup>+</sup> APCs may be made by the methods described herein, or by other methods in the art. Thus, in one aspect, the present invention comprises isolated antigen-presenting cells (APCs) selected as comprising APCs expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity sufficient to suppress proliferation of T cells (IDO<sup>+</sup> APCs). In another aspect, the present invention 30 comprises an isolated antigen-presenting cell selected as comprising expression of indoleamine 2,3-dioxygenase (IDO) enzyme activity at a level sufficient to suppress proliferation of T cells. In yet another aspect, the present invention comprises antigen-presenting cells comprising expression of indoleamine 2,3-dioxygenase (IDO) enzyme

activity at a level sufficient to suppress proliferation of T cells ( $IDO^+$  APCs) made by the methods of the present invention.

Alternatively, the present invention describes the generation of immunostimulatory (non-tolerance-inducing) APCs having reduced IDO expression ( $IDO^{LO}$  APCs). APCs 5 having reduced levels of IDO expression and exposed to antigens expressed by a tumor or pathogen (such as HIV) may be used as vaccines, by presenting cancer or pathogen antigens on APCs which contain fewer tolerance-inducing APCs.

Thus, in this aspect, the present invention comprises a method of making antigen-presenting cells (APCs) for enhancing T cell dependent immunologic activation in a subject 10 comprising the steps of:

- (a) isolating antigen-presenting cells (APCs) or their precursors (APC progenitors) from a subject; and
- (b) treating the isolated cells to select for APCs expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity not sufficient to cause suppression of T cell 15 proliferation ( $IDO^{LO}$  APCs).

In another aspect, the present invention comprises a method for increasing the number of non-suppressive antigen-presenting cells (APCs) in a subject comprising treating said subject to increase the population of antigen-presenting cells (APCs) or their precursors (APC progenitors) expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity not 20 sufficient to cause suppression of T cell proliferation ( $IDO^{LO}$  APCs).

In another aspect, the present invention comprises a method for increasing the protective immune response in a subject comprising the steps of:

- (a) isolating antigen-presenting cells (APCs) or their precursors (APC progenitors) from a first subject;
- (b) treating the isolated cells to select for APCs expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity not sufficient to cause suppression of T cell 25 proliferation ( $IDO^{LO}$  APCs); and
- (c) administering the treated cells from step (b) to the subject in an amount effective to generate a protective immune response in the subject.

30 The present invention also provides compositions for increasing T cell activation. Such compositions may be used to increase the T cell response to antigens in a subject. In this aspect, the present invention comprises isolated antigen-presenting cells (APCs) selected as comprising APCs expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity not sufficient to cause suppression of T cell proliferation ( $IDO^{LO}$  APCs). In another

aspect, the present invention comprises an isolated antigen-presenting cell (APC) selected as comprising levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity not sufficient to cause suppression of T cell proliferation. In yet another aspect, the present invention comprises antigen-presenting cells (APCs) comprising levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity not sufficient to cause suppression of T cell proliferation (IDO<sup>+</sup> APCs) made by the methods of the present invention.

The present invention also describes methods to quantitate the levels of immunosuppressive APCs in a population of APCs. Thus, in one aspect, the present invention comprises a method to determine the number of tolerance-inducing antigen-presenting cells (APCs) in a cell population comprising measuring the number of cells expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme sufficient to suppress proliferation of T cells (IDO<sup>+</sup> APCs) in the population. In another aspect, the present invention comprises a kit for determining the number of tolerance-inducing antigen-presenting cells (APCs) in a cell population comprising reagents to measure levels of indoleamine 2,3-dioxygenase (IDO) enzyme in the population of APCs, wherein the reagents are packaged in at least one individual container.

The immunosuppressive APCs may also be quantified using a biological assay. Thus, in another aspect, the present invention comprises a method to quantify the ability of a population of cells to suppress T cell proliferation comprising measuring the increase in T cell proliferation in the presence of an IDO inhibitor as compared to in the absence of an IDO inhibitor. The present invention also comprises a kit for determining the ability of a population of antigen-presenting cells to suppress T cell proliferation comprising an IDO inhibitor packaged in at least one individual container.

Additionally, the present invention provides for a diagnostic assay, based on detection of IDO<sup>+</sup> APCs and/or mip-3 $\alpha$  expression in tumors and tumor-draining lymph nodes. In this aspect, the present invention comprises a method for assessing the relative risk of tumor progression in a subject comprising the steps of:

- (a) assaying a sample of tissue from a tumor or tumor draining lymph node from a subject for expression of the enzyme indoleamine 2,3-dioxygenase (IDO); and
- (b) correlating the risk of tumor progression to IDO expression in the tissue sample, wherein IDO expression is positively correlated with an increase in the risk of tumor progression.

The present invention also comprises a method for assessing the risk of tumor progression in a subject comprising the steps of:

- (a) assaying a sample of tissue from a tumor or tumor draining lymph nodes from a subject for mip-3 $\alpha$  expression; and
- (b) correlating the risk of tumor progression to mip-3 $\alpha$  expression in the tissue sample, wherein mip-3 $\alpha$  expression is positively correlated with an increase in the risk of tumor progression.

5 The present invention also comprises kits for assessing the relative risk of tumor progression in a subject. For example, in one aspect, the present invention comprises a kit for assessing the relative risk of tumor progression in a subject comprising reagents for detection of the enzyme indoleamine 2,3-dioxygenase (IDO) in a sample of tissue from a tumor or 10 tumor draining lymph node from a subject, wherein the reagents are packaged in at least one individual container. In another aspect, the present invention comprises a kit for assessing the relative risk of tumor progression in a subject comprising reagents for detection of relative levels of expression of mip-3 $\alpha$  in a sample of tissue from a tumor or tumor draining lymph node from a subject, wherein the reagents are packaged in at least one individual 15 container.

10 The foregoing focuses on the more important features of the invention in order that the detailed description which follows may be better understood and in order that the present contribution to the art may be better appreciated. There are, of course, additional features of the invention which will be described hereinafter and which will form the subject matter of 20 the claims appended hereto. It is to be understood that the invention is not limited in its application to the specific details as set forth in the following description and figures. The invention is capable of other embodiments and of being practiced or carried out in various ways.

25 From the foregoing summary, it is apparent that an object of the present invention is to provide methods and compositions for enriching and isolating IDO $^+$  antigen-presenting cells for use in therapeutic applications such as the prevention of transplant rejection. In addition, it is apparent that an object of the present invention is to provide methods and compositions for isolating antigen-presenting cells depleted of IDO $^+$  antigen-presenting cells (i.e. IDO $^{LO}$  APCs) comprising reduced suppression or tolerance, as for example in cancer 30 prevention and therapy. These, together with other objects of the present invention, along with various features of novelty which characterize the invention, are pointed out with particularity in the claims and description provided herein.

BRIEF DESCRIPTION OF THE FIGURES

**FIG. 1** shows a schematic representation of a 3-step model for the regulation of IDO during dendritic cell (DC) differentiation in accordance with an embodiment of the present invention.

5       **FIG. 2** shows a schematic representation of methods to generate subsets of peripheral blood-derived APCs which are either: (1) enriched in tolerance-inducing APCs, as for example, for use in transplant therapy; or (2) depleted of tolerance-inducing APCs, as for example, for use in anti-cancer vaccines, in accordance with an embodiment of the present invention.

10       **FIG. 3** shows a schematic representation of tolerance-inducing antigen-presenting cells (APCs) comprising expression of intracellular indoleamine 2,3-dioxygenase (IDO), cell surface markers CD123, CD11c, and the chemokine receptor CCR6 juxtaposed next to tumor cells that express mip-3 $\alpha$ , in accordance with an embodiment of the present invention.

15       **FIG. 4** shows the regulation of IDO during maturation in accordance with an embodiment of the present invention wherein (A) shows DCs cultured in GMCSF+IL4 for 7 days with and without the addition of 1-methyl-(D)-tryptophan; (B) shows the same DCs matured with a cocktail of cytokines (IL1 $\beta$ , TNF $\alpha$ , IL6, prostaglandin E2 (PGE2)); and (C) shows the same DCs matured with monocyte-conditioned medium. In all groups there is significant IDO-mediated suppression.

20       **FIG. 5** shows expression of CD123, the chemokine receptor CCR6, and indoleamine 2,3-dioxygenase (IDO) by antigen-presenting cells in accordance with an embodiment of the present invention. In panels (A) and (B), human monocytes were cultured to produce myeloid dendritic cells (A) or macrophages (B), and then both groups received interferon- $\gamma$  during the final 18 hrs of culture and harvested cells were triple-stained for CD123, CD11c and IDO. In (A) and (B), panels on the right show expression of IDO and CD123 in the gated CD11c $^+$  population shown on the left. In (C) myeloid dendritic cells, cultured as in panel (A), were triple-stained for CD123, IDO, and the chemokine receptor CCR6. Both panels show the entire (ungated) population. In (D), the adherent (non-dendritic) population of APCs is shown, taken from a culture similar to panel (A) but using serum-free conditions. 25 Cells were stained for IDO and CD123. Panel (E) compares IDO-mediated suppression by DCs and non-dendritic APCs from the same culture where IDO-mediated suppression is the difference in thymidine incorporation in T cells in the absence (stippled bars) vs. the presence (striped bars) of 1-methyl-(D,L)-tryptophan (1-MT).

**FIG. 6** shows suppression of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase/CD123 expressing (IDO<sup>+</sup>/CD123<sup>+</sup>) dendritic cells in accordance with an embodiment of the present invention. Panel (A) shows myeloid dendritic cells which were activated for 24 hrs with TNF $\alpha$ , and labeled with anti-CD123 antibody and enriched by sorting (CD123<sup>+</sup>) with goat anti-mouse secondary antibody conjugated to magnetic beads (immunosorting), wherein the left panel shows the population prior to enrichment and the right panel shows the population after enrichment. Panel (B) shows a comparison of the effect of CD123<sup>+</sup> enriched and CD123<sup>+</sup> depleted cells on allogeneic T cell proliferation as measured in a mixed-leukocyte reaction by thymidine incorporation in the absence (■) or the presence (□) of 1-methyl-(D,L)-tryptophan (1-MT; an inhibitor of IDO). Panel (C) shows experiments similar to panel (B), using 3 different pairs of donors, each allogeneic to the other, and each pair pre-tested to produce an active allogenic mixed leukocyte reaction (MLR) using sorted CD123<sup>+</sup> cells without (■) or with (□) 1-MT.

**FIG. 7** shows that sorting to generate a population of cells enriched for CD123 expression (CD123<sup>+</sup>) by immunosorting results in APCs are enriched for cells having high levels of IDO expression (IDO<sup>+</sup> APCs) in accordance with an embodiment of the present invention.

**FIG. 8** shows detection of IDO-expressing (IDO<sup>+</sup>) CD123<sup>+</sup> dendritic cells in human tumors and draining lymph nodes in accordance with an embodiment of the present invention. Panel (A) shows a positive control for IDO (brown) in syncytiotrophoblast cells of term human placenta (inset: the same tissue, but with anti-IDO antibody neutralized by an excess of the immunizing peptide and shown at half scale). Panel (B) shows a malignant melanoma primary cutaneous tumor stained for IDO (arrows) (Fast Red chromogen). Panel (C) shows a draining lymph node of a malignant melanoma, showing accumulation of IDO-expressing cells (red) in the lymphoid and perivascular regions of the node, but sparing the macrophage-rich sinuses (asterisk). Panel (D) shows a higher magnification of panel (C), with a characteristic collection of IDO-expressing cells (dark signal) around a high-endothelial venule (V). Panel (E) shows a low-power view of a draining lymph node containing heavily pigmented metastatic melanoma cells (endogenous melanin, black; darkest signal), with confluent infiltration of IDO-expressing cell (red; next darkest signal) around the tumor deposits. Panel (F) shows normal lymphoid tissue with scattered IDO<sup>+</sup> cells (red; scattered dark signals) in a germinal center (GC) and T cell regions (T) of a human pharyngeal tonsil from a routine tonsillectomy. Panels (G) and (H) (higher magnification of

the region in panel (G) indicated by the arrow) shows co-localization of cells expressing IDO (brown; darkest cytoplasmic signal) and mip-3 $\alpha$  (red; next darkest cytoplasmic signal) in the lamina propria of the small intestine, particularly in the subepithelial areas overlying mucosal lymphoid aggregates (LA). Panels (I) and (J) (higher magnification of the region in panel (I) indicated by the arrow) shows expression of mip-3 $\alpha$  (red; darkest cytoplasmic signal) by tumor cells in a lesion of malignant melanoma metastatic to lymph node, such that the mip-3 $\alpha^+$  cells are scattered throughout the tumor (T), while the IDO $^+$  (brown) cells are congregated at the margins of the metastasis but confined to the residual lymph node tissue (LN).

FIG. 9 shows expression of mip-3 $\alpha$  mRNA by human tumors in accordance with an embodiment of the present invention. RNA from melanomas (M, n=18), renal cell carcinomas (R, n=19) or non-small cell lung cancers (L, n=9) was analyzed for expression of mip-3 $\alpha$  by quantitative PCR calculated as the ratio of mip-3 $\alpha$  to the GAPDH housekeeping gene in each sample.

15

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention describes the isolation of myeloid-derived antigen-presenting cells (APCs) which are enriched for tolerance-inducing APCs, or depleted of tolerance-inducing APCs, and the use of these cells for various therapeutic applications. The present invention relies on the discovery that antigen-presenting cells may be separated into a tolerance-inducing population, which is associated with high levels of expression of the enzyme indoleamine-2,3-dioxygenase (IDO), and a T cell activating (non-tolerance-inducing) population, which is associated with low levels of expression of IDO. For example, APCs having high levels of IDO (IDO $^+$  APCs), and constitutively expressing or exposed to donor tissue antigens may be used to increase tolerance of the recipient to the donor's tissue in transplant therapy by presenting the antigens on tolerance-inducing APCs. Alternatively, APCs having reduced levels of IDO expression (IDO $^{LO}$  APCs) and exposed to antigens expressed by cancer tissue or virus may be used as anti-cancer vaccines or anti-viral vaccines, respectively, by presenting the antigens on APCs depleted on tolerance-inducing cells.

25

Thus, the current invention teaches that conventional preparations of human APCs can contain two independent subsets: an IDO $^+$  subset (comprising relatively high levels of IDO expression); and an IDO $^{LO}$  subset (comprising little to no IDO expression). Moreover, which of these two types of APC predominates is highly (and in some cases unpredictably)

dependent on the culture conditions or other variables. In many applications, even a minor contaminating admixture of the undesired type of APC (*i.e.* IDO<sup>LO</sup> vs. IDO<sup>+</sup>) may render the APC population unusable, or even harmful, for the desired application. For example, if the goal is to generate tolerance toward donor histocompatibility antigens prior to organ transplantation, exposure to even a minority of activating dendritic cells could promote worsened rejection. Conversely, if the goal is to enhance responses to weak tumor antigens, the presence of even a minor population of IDO<sup>+</sup> tolerance-inducing cells may be enough to suppress the desired response (*see e.g.*, Grohmann, U., *et al.*, *J. Immunol.* **167**: 708-714 (2001), for studies in murine model).

10 Thus, in one aspect, the present invention describes a method of making antigen-presenting cells (APCs) for enhancing T cell tolerance comprising the steps of:

- (a) isolating antigen-presenting cells (APCs) or their precursors (APC progenitors) from a first subject; and
- (b) treating the isolated cells to select for tolerance-inducing APCs expressing 15 levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity sufficient to suppress proliferation of T cells (IDO<sup>+</sup> APCs).

20 Preferably, the tolerance-inducing IDO<sup>+</sup> APCs comprise at least 90% of the APC population expressing IDO at levels of at least 2-fold over background. More preferably, the tolerance-inducing IDO<sup>+</sup> APCs comprise at least 95% of the APC population expressing IDO at levels of at least 2-fold over background.

25 Alternatively, IDO<sup>+</sup> APCs may be quantitated by measuring the biological activity of the preparation. Thus, in an embodiment, the tolerance-inducing IDO<sup>+</sup> APCs comprise suppressor activity, comprising an at least a 2-fold increase in T cell proliferation in the presence of an IDO inhibitor as compared to in the absence of an IDO inhibitor. Suppressor activity may be measured using a mixed leukocyte reaction or similar assay of T cell proliferation. Preferably, the IDO inhibitors comprise 1-methyl-(D,L)-tryptophan,  $\beta$ -(3-benzofuranyl)-(D,L)-alanine,  $\beta$ -(3-benzo(b)thienyl)-(D,L)-alanine, or 6-nitro-(D,L)-tryptophan. More preferably, the IDO inhibitors comprise 1-methyl-(D)-tryptophan or 6-nitro-(D)-tryptophan.

30 In an embodiment, the isolated APCs or APC progenitors comprise mature blood-derived dendritic cells, mature tissue dendritic cells, monocyte-derived macrophages, non-dendritic APCs, B cells, plasma cells, or any mixture thereof. Preferably, the isolated APCs or APC progenitors comprise a cell type bearing markers of antigen presentation and costimulatory function. Also preferably, the APCs or APC progenitors are isolated from

peripheral blood, bone marrow, lymph nodes or a solid organ from a human or other mammal.

The treatment to select for IDO<sup>+</sup> APCs may comprise predetermined culture conditions or physical selection. Preferably, step (b) comprises culturing the cells in medium which is essentially free of serum. Also preferably, step (b) comprises culturing the cells in the presence of granulocyte-macrophage colony stimulating factor (GMCSF). Step (b) may also comprise culturing the cells in the presence of macrophage colony stimulating factor (MCSF). In addition, step (b) may comprise culturing the cells in the presence of IL4. Step (b) may also comprise culturing the cells in the presence of TGF $\beta$  and/or IL10. For example, in an embodiment, a cytokine cocktail such as those known in the art (Jonuleit, H., *et al.*, *Eur. J. Immunol.*, 27: 3135-3142 (1997)) may be employed.

In an embodiment, step (b) also comprises culturing the cells with an agent to cause or regulate maturation of those APCs that express high levels of IDO. Such maturation agents may include, but are not limited to TNF $\alpha$ , IL10, TGF $\beta$ , CD40-ligand, activating anti-CD40 antibodies, cells engineered to express cell-surface CD40-ligand, proinflammatory bacterial or pathogen products, or any combination thereof. Thus, for selection of IDO<sup>+</sup> APCs these agents may be combined singly, or added together with other agents used for the maturation of DCs (Jonuleit, H., *et al.*, *Eur. J. Immunol* 27: 315-3142 (1997); Reddy, A., *et al.*, *Blood* 90: 3640-3646 (1997)).

In an embodiment, step (b) may comprise genetically modifying the APCs or APC progenitors such that the final preparation comprises APCs expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity sufficient to suppress proliferation of T cells (IDO<sup>+</sup> APCs). As an example, transfection of the culture of APCs or APC progenitors with a gene for a cytokine or ligand may be employed (Kikuchi, T., *et al.*, *Blood* 98: 91-99 (2000); Gorckynski, R., *et al.*, *Transplantation Proceedings* 33: 1565-1566 (2001); Morita, Y., *et al.*, *J. Clin. Invest.*, 107: 1275-1284 (2001)).

In an embodiment, the method utilizes cell surface proteins or other markers for separation (enrichment or depletion) of IDO<sup>+</sup> cells from other APCs. Thus, in an embodiment, the method includes measuring expression of at least one cell surface marker that identifies the APCs as expressing levels of IDO sufficient to suppress T cell proliferation (IDO<sup>+</sup> APCs) or as expressing levels of IDO not sufficient to suppress T cell proliferation (IDO<sup>LO</sup> APCs). Preferably, the cell surface marker is used to separate IDO<sup>+</sup> APCs from IDO<sup>LO</sup> APCs. The markers used for differential selection of IDO<sup>+</sup> cells from IDO<sup>LO</sup> cells include, but are not limited to, CD123, CD11c, CCR6, CD14 or any combination thereof.

Alternatively, the method may include differential adhesion to a substrate to separate APCs that expressing levels of IDO sufficient to suppress T cell proliferation (IDO<sup>+</sup>APCs) from APCs expressing levels of IDO not sufficient to suppress T cell proliferation (IDO<sup>LO</sup>APCs).

One object of the present invention is to develop tolerance-promoting APCs that 5 present a specific subset of antigens of interest. For example, tolerance-promoting APCs that present antigens from a donor may be administered to a transplant recipient to promote acceptance of a graft or transplant. Thus, in an embodiment, the subject from which the 10 APCs or APC progenitors are isolated comprises a tissue donor to a second subject. In another embodiment, the APCs or APC progenitors are isolated from a subject with an autoimmune disorder for subsequent preparation of IDO<sup>+</sup>APCs for use in treating the 15 disorder.

In addition, the treated APCs may be exposed to at least one source of antigen after 20 isolation from a subject and treatment to select for IDO<sup>+</sup>APCs. In an embodiment, the antigen comprises a purified, or a synthetic or recombinant polypeptide representing a specific antigen to which it is desired that tolerance be induced, or a short synthetic 25 polypeptide fragment derived from the amino acid sequence of such an antigen. Preferably, the source of antigen comprises antigens expressed by a donor tissue graft. Also preferably, the source of antigen comprises protein or other material to which a patient has an autoimmune disorder (see e.g. Yoon, J.-W., *et al.*, *Science* 284: 1183-1187 (1999) for 30 examples of such proteins). In yet another embodiment, the method comprises transfecting or genetically engineering the IDO<sup>+</sup>APCs to express at least one antigenic polypeptide.

The tolerance-inducing APCs or their precursors (or non-tolerance inducing APCs or 25 their precursors) as defined by the methods of the present invention may also be increased in number in a subject by administering to the subject agents that increase the number of the desired APCs. Numerous cytokines and other agents have been shown to increase the 30 number of one or more of different types of APCs when administered *in vivo*. Examples of such agents include MCSF, GMCSF, granulocyte colony-stimulating factor (GCSF), FLT3-ligand, and other natural and artificial cytokines and hematopoietic growth factors.

Previously, however, it was not known whether the APCs induced by such treatments were 35 tolerance-inducing or non-tolerance-inducing or a mixture of both. The present invention provides the discovery that by measuring IDO expression following isolation and *in vitro* treatment of the desired APC population, the effectiveness of such *in vivo* treatments can be evaluated and improved upon. In addition, as described herein, the present invention provides methods to quantify IDO expression, both on a cell-by-cell basis and as a biological

assay for bulk populations. Thus, in an embodiment, tolerogenic APCs or their precursors in peripheral blood from a donor may be increased by treatment with selected cytokines prior to isolation for in vitro culture and delivery to a recipient for the purpose of inducing transplantation tolerance.

5 Thus, in one aspect, the present invention comprises a method for increasing the number of tolerance-inducing antigen-presenting cells (APCs) in a subject comprising treating the subject to increase the production of APCs or their precursors (APC progenitors) expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity sufficient to suppress proliferation of T cells (IDO<sup>+</sup> APCs).

10 In another aspect, the present invention comprises a method for enhancing tolerance in a subject comprising the steps of:

- (a) isolating antigen-presenting cells (APCs) or their precursors (APC progenitors) from a first subject;
- (b) treating the cells to select for APCs expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity sufficient to suppress proliferation of T cells (IDO<sup>+</sup> APCs); and
- (c) administering the treated cells of step (b) to the original subject or to a second subject in an amount effective to generate a tolerance-promoting response in said recipient subject.

20 Preferably, the tolerance-promoting response reduces T cell activation in the recipient subject. Also preferably, the tolerance-promoting response prolongs the survival of transplanted cells or tissues in the recipient subject. Also preferably, the tolerance-promoting response reduces the symptoms of an autoimmune disease in the recipient subject.

25 In an embodiment, the subject from which the APCs or APC progenitors are isolated comprises a tissue donor to the recipient subject. In another embodiment, the subject from which the APCs or APC progenitors are isolated comprises a mammal with an autoimmune disorder.

The method may include exposing the APCs or APC progenitors to at least one source of antigen after isolation from the first subject and treatment to select for IDO<sup>+</sup> APCs.

30 Preferably, the antigen comprises a synthetic or natural polypeptide. Also preferably, the antigen comprises at least one antigen expressed by a donor tissue graft. Alternatively, the antigen may comprise at least one antigen to which the recipient subject has an autoimmune disorder. In another embodiment, the method may comprise transfecting or genetically engineering the APCs selected as IDO<sup>+</sup> to express at least one antigenic polypeptide.

The present invention also provides compositions for enhancing T cell tolerance.

Such tolerizing APCs may be used to promote acceptance of graft or transplant tissue from a donor subject in a recipient or to treat a patient with autoimmune disease. In this aspect, the present invention comprises isolated antigen-presenting cells (APCs) selected as comprising 5 APCs expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity sufficient to suppress proliferation of T cells (IDO<sup>+</sup> APCs). In another aspect, the present invention comprises an isolated antigen-presenting cell selected as comprising expression of indoleamine 2,3-dioxygenase (IDO) enzyme activity at a level sufficient to suppress proliferation of T cells. In yet another aspect, the present invention comprises antigen-presenting cells comprising expression of indoleamine 2,3-dioxygenase (IDO) enzyme 10 activity at a level sufficient to suppress proliferation of T cells (IDO<sup>+</sup> APCs) made by the methods of the invention.

Preferably, the isolated IDO<sup>+</sup> APCs comprise at least 90% of the APC population expressing IDO at levels of at least 2-fold over background. More preferably, the isolated 15 IDO<sup>+</sup> APCs comprise at least 95% of the APC population expressing IDO at levels of at least 2-fold over background. Also preferably, the isolated IDO<sup>+</sup> APCs comprise suppressor activity comprising an at least a 2-fold increase in T cell proliferation in the presence of an IDO inhibitor as compared to in the absence of an IDO inhibitor. In an embodiment, the isolated IDO<sup>+</sup> APCs express at least one antigenic polypeptide.

20 In an embodiment, the isolated cells comprise at least one cell surface marker that identifies the cells as expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity sufficient to suppress T cell proliferation (IDO<sup>+</sup> APCs). Preferably, the marker comprises CD123, CD11c and CCR6.

25 In an embodiment, the composition of the present invention includes a pharmaceutically acceptable carrier. Also preferably, the composition of the present invention includes one or more immunosuppressive pharmaceuticals in a unit dosage form.

30 In another aspect, the present invention comprises the generation of immunostimulatory cells. Such cells may be used to stimulate the immune response, as for example, to cancer-related antigens or viral-related antigens. Thus, in this aspect, the present invention comprises a method of making antigen-presenting cells (APCs) for enhancing T cell dependent immunologic activation in a subject comprising the steps of:

- (a) isolating antigen-presenting cells (APCs) or their precursors (APC progenitors) from a subject; and

(b) treating the isolated cells to select for APCs expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity not sufficient to cause suppression of T cell proliferation (IDO<sup>LO</sup> APCs).

Preferably, the IDO<sup>LO</sup> APCs comprise a population of APCs having less than 10% of the population expressing IDO at a level of greater than 2-fold over background. More preferably, the IDO<sup>LO</sup> APCs comprise a population of APCs having less than 5% of the population expressing IDO at a level of greater than 2-fold over background. Alternatively, the IDO<sup>LO</sup> APCs may be quantitated using a T cell proliferation assay such as a mixed leukocyte reaction or similar methods, wherein IDO<sup>LO</sup> APCs comprise an absence of suppressor activity comprising a less than a 1.5-fold increase in T cell proliferation in the presence of an IDO inhibitor as compared to in the absence of an IDO inhibitor. Preferably, the IDO inhibitor comprises 1-methyl-(D,L)-tryptophan,  $\beta$ -(3-benzofuranyl)-(D,L)-alanine,  $\beta$ -(3-benzo(b)thienyl)-(D,L)-alanine, or 6-nitro-(D,L)-tryptophan. Also preferably, the IDO inhibitor comprises 1-methyl-(D)-tryptophan or 6-nitro-(D)-tryptophan.

Preferably, the isolated APCs or APC progenitors comprise mature blood-derived dendritic cells, mature tissue dendritic cells, monocyte-derived macrophages, non-dendritic APCs, B cells, plasma cells, or any mixture thereof. Also preferably, the isolated APCs or APC progenitors comprise a cell type bearing markers of antigen presentation and costimulatory function. Also preferably, the APCs or APC progenitors are isolated from peripheral blood, bone marrow, lymph nodes or a solid organ from a human or other mammal.

The treatment to select for IDO<sup>LO</sup> APCs may comprise predetermined culture conditions or physical selection. In an embodiment, treatment of APCs and progenitor APCs to select for IDO<sup>LO</sup> APCs comprises culturing the cells in the presence of serum-free medium. In other embodiments, treatment of APCs and progenitor APCs to select for IDO<sup>LO</sup> APCs comprises culturing the cells in the presence of MCSF, or GMCSF, or interferon- $\alpha$ , or combinations thereof. In an embodiment, treatment of APCs and progenitor APCs to select for IDO<sup>LO</sup> APCs comprises culturing the cells with an agent to cause maturation of those APCs that express low levels of IDO (IDO<sup>LO</sup> APCs). Preferably, the maturation agents comprise TNF $\alpha$ , CD40-ligand (CD40L), activating anti-CD40 antibodies, cells engineered to express cell-surface CD40-ligand, proinflammatory bacterial or pathogen products, or any combination thereof. Alternatively (or additionally), the APCs may genetically engineered to express CD40-ligand. The treatment may also comprise culturing the cells in the presence of neutralizing antibodies for IL10 and/or TGF $\beta$ . Thus, for selection of IDO<sup>LO</sup> APCs, these

agents may be combined singly, or added together with other agents used for the maturation of DCs (Jonuleit, H., *et al.*, *Eur. J. Immunol.* 27: 315-3142 (1997); Reddy, A., *et al.*, *Blood* 90: 3640-3646 (1997).

5 Alternatively, step (b) may comprise genetically modifying the APCs or APC progenitors such that the final preparation comprises APCs expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity not sufficient to suppress T cell proliferation (IDO<sup>LO</sup> APCs).

10 In an embodiment, the method utilizes cell surface proteins or other markers for selection of IDO<sup>LO</sup> cells from other APCs. Thus, in an embodiment, the method includes measuring expression of at least one cell surface marker that identifies the APCs as expressing levels of IDO not sufficient to suppress T cell proliferation (IDO<sup>LO</sup>) or as expressing levels of IDO (IDO<sup>+</sup>). Preferably, the cell surface marker is used to separate APCs that express low levels of IDO (IDO<sup>LO</sup> APCs) from APCs that express high levels of IDO sufficient to suppress T cell proliferation (IDO<sup>+</sup> APCs). The markers used for 15 differential selection of IDO<sup>LO</sup> cells from IDO<sup>+</sup> cells include, but are not limited to, CD123, CD11c, CCR6, CD14 or any combination thereof. Alternatively, the method may include differential adhesion to a substrate to separate APCs that express levels of IDO not sufficient to suppress T cell proliferation (IDO<sup>LO</sup> APCs) from APCs that express levels of IDO sufficient to suppress T cell proliferation (IDO<sup>+</sup> APCs).

20 One object of the present invention is to develop immunogenic APCs that present a specific subset of antigens of interest. For example, APCs depleted of tolerance-inducing cells (i.e. IDO<sup>LO</sup> APCs) may be used to present antigens expressed by a tumor or a pathogen to a subject to increase the immune response to such antigens. Thus, in an embodiment the method includes exposing the treated APC preparation to at least one source of antigen after 25 isolation and selection of IDO<sup>LO</sup> APCs. In an embodiment, the antigen comprises at least one synthetic or natural polypeptide. Preferably, the antigen is expressed by a tumor. Also preferably, the antigen is expressed by a pathogen. Alternatively, the method may comprise transfecting or genetically engineering the IDO<sup>LO</sup> APCs to express at least one antigenic polypeptide.

30 In another aspect, the present invention comprises a method for increasing the number of non-suppressive antigen-presenting cells (APCs) in a subject comprising treating the subject to increase the population of APCs or their precursors (APC progenitors) expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity not sufficient to cause suppression of T cell proliferation (IDO<sup>LO</sup> APCs).

In another aspect, the present invention comprises a method for increasing the protective immune response in a subject comprising the steps of:

- (a) isolating antigen-presenting cells (APCs) or their precursors (APC progenitors) from a first subject;
- 5 (b) treating the isolated cells to select for APCs expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity not sufficient to cause suppression of T cell proliferation (IDO<sup>LO</sup> APCs); and
- (c) administering the treated cells of step (b) back into the subject in an amount effective to generate a protective immune response in the subject.

10 Preferably, a protective immune response comprises a reduction in proliferation of tumor cells or a reduction in the clinical progression of a malignancy. Also preferably, a protective response is associated with a reduced pathogen load or increased resistance to at least one pathogen.

15 In an embodiment, the method is used to increase the immune response to a specific subset of antigens. Thus, in an embodiment, the method includes exposing the treated cells of step (b) to at least one source of antigen after isolation from the first subject. In an embodiment, the antigen comprises a natural or synthetic polypeptide. Preferably, the antigen is expressed by a tumor. Also preferably, the antigen is expressed by a pathogen. In another embodiment, the method comprises transfecting or genetically engineering the 20 treated cells of step (b) to express at least one antigenic polypeptide.

25 The present invention also provides composition for increasing T cell activation. Such compositions may be used to increase the T cell response to antigens in a subject. In this aspect, the present invention comprises isolated antigen-presenting cells (APCs) selected as comprising APCs expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity not sufficient to cause suppression of T cell proliferation (IDO<sup>LO</sup> APCs). In another aspect, present invention comprises an isolated antigen-presenting cell (APC) selected as comprising levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity not sufficient to cause suppression of T cell proliferation. In yet another aspect, the present invention 30 comprises antigen-presenting cells (APC) comprising levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity not sufficient to cause suppression of T cell proliferation (IDO<sup>LO</sup> APCs) made by the methods of the invention.

Preferably, the IDO<sup>LO</sup> cells comprise a population of APCs having less than 10% of the population expressing IDO at a level of greater than 2-fold over background. More preferably, the IDO<sup>LO</sup> cells comprise a population of APCs having less than 5% of the

population expressing IDO at a level of greater than 2-fold over background. Also preferably, the IDO<sup>LO</sup> APCs comprise an absence of suppressor activity comprising less than a 1.5-fold increase in T cell proliferation in the presence of an IDO inhibitor as compared to in the absence of an IDO inhibitor.

5 In an embodiment, the IDO<sup>LO</sup> APCs comprise at least one cell surface marker that identifies the cells as expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity not sufficient to cause suppression of T cell proliferation (IDO<sup>LO</sup>). Preferably, the marker comprises CD14. Also preferably, the marker causes preferential adhesion of the cells to plastic. Preferably, the composition comprises a pharmaceutically acceptable carrier.

10 APCs as IDO<sup>+</sup> and IDO<sup>LO</sup> Populations

The present invention relies on the discovery that APCs expressing high levels of the intracellular enzyme indoleamine 2,3-dioxygenase (IDO) are capable of suppressing T cell responses *in vitro* and *in vivo*. Thus, the present invention is based on the discovery that the tryptophan-degrading enzyme indoleamine 2,3-dioxygenase (IDO) is an intrinsic attribute of 15 APCs that determines whether or not the APC is immunosuppressive or immunostimulatory.

15 Immunologic tolerance is operationally defined as the absence of an immunologic rejection response toward specific tissues or antigens. Conceptually, there are two types of tolerance: pre-existing tolerance to self, and acquired tolerance to new antigens. For example, immunocompetent mice become anergic (non-reactive) even to non-self antigens when these 20 are introduced on tumors (Staveley-O'Carroll, K., *et al.*, *Proc. Natl. Acad. Sci. USA*, **95**: 1178-1183 (1998)). This anergy is apparently caused, not by the tumor cells themselves, but by cross-presentation of tumor antigens by tolerogenic bone marrow-derived APCs (Sotomayor, E.M., *et al.*, *Blood*, **98**: 1070-1077 (2001)).

20 Tolerogenic APCs are potent regulators of the immune response because they can 25 create networks of immunoregulatory (suppressor) T cells. These regulatory T cell networks are apparently involved in both maintaining normal tolerance to self, and also in mediating a state of acquired unresponsiveness to non-self antigens (e.g. Sakaguchi, S., *Cell*, **101**: 455-459 (2000); H. Waldmann and S. Cobbold, *Immunity*, **14**: 399-406 (2001); Shevach, E.M., *J. Exp. Med.*, **193**: F41-F46 (2001)). For example, it has been shown that tumor-specific 30 regulatory T cells exist, and that blocking or depleting these cells facilitates the ability to break tolerance to tumor antigens (Sutmuller, R.P.M., *et al.*, *J. Exp. Med.*, **194**: 823-832 (2001); van Elsas, A., *et al.*, *J. Exp. Med.*, **190**: 355-366 (1999); van Elsas, A., *et al.*, *J. Exp. Med.*, **194**: 481-490 (2001)). Once established, this type of unresponsiveness is self-perpetuating, transferable, and can even "spread" to encompass new antigens encountered in

the same context as those to which the network is already tolerant (S. Cobbold and H. Waldmann, *Curr. Opin. Immunol.*, **10**: 518-524 (1998)). When present, regulatory T cells tend to be dominant, enforcing functional tolerance throughout the entire immune system even in the face of other, non-tolerant T cells (Honey, K., *et al.*, *Immunol. Res.*, **20**: 1-14 (1999)). It is known that certain types of human APCs are able to promote such regulatory T cells (Jonuleit, H., *Trends in Immunol.* **22**: 394-400 (2001); Dhodapkar, M.V., *et al.*, *J. Exp. Med.*, **193**: 233-238 (2001)). However the mechanism by which this occurs is unknown. Clearly, the ability to create such potent regulatory T cells is highly desirable in settings such as organ transplantation or autoimmunity. Conversely, it is undesirable (but often occurs) to inadvertently create such cells when immunizing against antigens (e.g. from pathogens or tumors).

The enzyme indoleamine 2,3-dioxygenase (IDO) is an intracellular heme-containing enzyme that catalyzes the initial rate-limiting step in tryptophan degradation along the kynurenine pathway (M.W. Taylor and G. Feng, *FASEB J.*, **5**: 2516-2522 (1991)). It has been proposed that IDO suppresses T cell proliferation by degrading tryptophan in the local environment (Munn, D.H., *et al.*, *J. Exp. Med.*, **189**: 1363-1372 (1999)). Two types of human APCs, (1) monocyte-derived macrophages (Munn, D.H., *et al.*, *J. Exp. Med.*, **189**: 1363-1372 (1999)), and (2) monocyte-derived dendritic cells (Hwu, P., *et al.*, *J. Immunol.* **164**: 3596-3599 (2000)), which suppress T cell activation *in vitro* have been shown to express the tryptophan-degrading enzyme indoleamine 2,3-dioxygenase (IDO). In mice, IDO has been implicated in the tolerance displayed by the maternal immune system toward the immunologically disparate fetus (Mellor, A.L., *et al.*, *Nat. Immunol.* **2**: 64-68 (2001); Munn, D.H., *et al.*, *Science*, **281**: 1191-1193 (1998)), as well as in acquired tolerance toward antigens presented by murine CD8 $\alpha$ <sup>+</sup> dendritic cells (Grohmann, U. *et al.*, *J. Immunol.*, **167**: 708-714 (2001)). Also, IDO is required for the induction of spontaneous tolerance by liver allografts (Miki, T., *et al.*, *Transplantation Proceedings* **33**: 129-130 (2000)), a process which is thought to be mediated by graft associated DCs (Thompson, A.W. and Lu, L., *Immunol. Today* **20**: 27-31 (1999)). A direct mechanistic link between IDO gene expression and suppression of antigen-specific T cell responses *in vivo* has been shown in a mouse model by the inventors (Mellor, A.L., *et al.*, *J. Immunol.* **168**: 3771-3776 (2002)), wherein transfection of the mouse IDO gene into murine cell lines causes: (1) suppression of T cell responses to antigens presented by the IDO-expressing cell lines; and (2) abrogation of the ability of the cells to prime an allogenic T cell response *in vivo* to antigens.

There are several ways to measure IDO expression. As defined herein, cells comprising high levels of IDO activity comprise: (1) a level of IDO activity sufficient to suppress T cell proliferation either *in vitro* or *in vivo*; (2) a level of IDO protein or RNA significantly above the background level of the assay; or (3) at least 90% of APCs in the preparation expressing IDO as enumerated on a cell-by-cell basis. For example, high level IDO expression (IDO<sup>+</sup>) is defined by flow cytometry quantitatively on a cell by cell basis as expression of antigenic IDO protein at a level of at least 2-fold above background, more preferably, at a level of at least 5-fold above background, and even more preferably, at a level of at least 10-fold over background. In this assay, background may be defined as neutralization of an anti-IDO antibody using standard techniques such as binding with an excess of an immunizing peptide (polyclonal antibody assay) or binding of an isotype-matched control (monoclonal antibody assay). Thus, in an embodiment of the present invention, tolerance-inducing IDO+ APCs comprise at least 90% of the APC population expressing IDO at levels of at least 2-fold over background, and more preferably, at least 95% of the APC population expressing IDO at levels of at least 2-fold over background.

IDO protein and RNA levels can also be measured by other techniques including western blot, immunohistochemistry, northern blot, reverse-transcriptase polymerase chain reaction (RT-PCR), or *in situ* hybridization. Preferably, using the techniques of immunohistochemistry or *in situ* hybridization, IDO expression is measured on a cell-by-cell basis. Cells expressing IDO are defined relative to the appropriate negative control for the particular assay as understood by one skilled in the art. Preferably, the IDO-expressing APCs comprise at least 90% of the APC population in such an assay, and more preferably, at least 95% of the APC population. IDO can also be measured by western blot, northern blot, RT-PCR, and other assays that measure IDO in a bulk population. High level IDO expression (IDO<sup>+</sup>) for a bulk population is defined as IDO-specific signal of at least 2-fold over the negative control for the particular assay; as understood by one skilled in the art, or preferably, at a level of at least 5-fold over background, and more preferably, at a level of at least 10-fold over background.

Low levels of IDO expression (IDO<sup>LO</sup>) may also be defined by flow cytometry or other assays quantitatively on a cell-by-cell basis with reference to the percentage of cells expressing IDO. Thus, in an embodiment, IDO<sup>LO</sup> cells comprise APCs wherein a minority of APCs in the preparation expressing IDO protein at a level of at least 2-fold over background. In an IDO<sup>LO</sup> preparation of APCs, preferably less than 10% of the APCs express IDO protein at a level of at least 2-fold over background, more preferably less than 5% of the APCs

express IDO protein at a level of at least 2-fold over background. Alternatively, IDO is measured by immunohistochemistry, *in situ* hybridization or other techniques that measure IDO on a cell-by-cell basis, and an IDO<sup>LO</sup> preparation is defined as comprising less than 20% IDO-expressing cells, or more preferably less than 10% IDO-expressing cells, and even more preferably, less than 5% IDO-expressing cells. Alternatively, IDO expression is measured in a bulk population, such that IDO-specific signal is less than 2-fold over the negative control for the particular assay.

10 Alternatively, an assay to measure biological activity such as a T cell proliferation assay is used to quantify IDO activity. A T cell proliferation assay includes, but is not limited to, a mixed leukocyte reaction (MLR) assay, or stimulation of T cells with antigen or mitogen.

15 Thus, in an embodiment, high level IDO expression (IDO<sup>+</sup>) is defined as a greater than 2-fold increase in T-cell proliferation when an inhibitor of IDO is added to MLRs containing the preparation of interest. This assay provides a physiological basis to quantify the amount of T-cell proliferation that has been suppressed by IDO (*i.e.* the MLR without the IDO inhibitor compared to the MLR with the IDO inhibitor). Preferably, the MLR contains the APC preparation to be administered plus allogeneic or xenogeneic T cells. Alternatively, the T cell proliferation assay may contain the APC preparation to be administered plus autologous T cells and an antigen or mitogen to serve as the stimulus for T cell proliferation.

20 High level IDO expression (IDO<sup>+</sup>) is defined as a greater than 2-fold increase in T cell proliferation when an inhibitor of IDO is added to co-cultures containing the preparation of interest.

25 T cell proliferation assays may also be used to quantify low IDO activity. Thus, in an embodiment, low IDO activity (IDO<sup>LO</sup>) is defined by an allogenic MLR or autologous antigen or mitogen-stimulation assay as less than 1.5 fold increase in T cell proliferation when an inhibitor of IDO is added to co-cultures containing the APC preparation of interest.

30 As defined herein, an inhibitor of IDO is an agent capable of preventing tryptophan degradation and/or kynurenine production by IDO enzyme in a cell free system, or by cells expressing IDO. For example, the inhibitor of IDO is an agent capable of preventing tryptophan degradation and/or kynurenine production by isolated human monocyte-derived macrophages activated by interferon- $\gamma$  (Munn, D.H., *et al.*, *J. Exp. Med.*, **189**: 1363-1372 (1999)). Preferably, the inhibitor of IDO is an analogue of tryptophan. More preferably, the inhibitor of IDO is the (D) isomer analogue of tryptophan rather than the (L) analogue, as in some cases only the (D) isomer reveals true suppression of T-cell activation by IDO. Thus in

an embodiment, the inhibitor of IDO comprises 1-methyl-(D,L)-tryptophan,  $\beta$ -(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan) (1-MT),  $\beta$ -[3-benzo(b)thienyl]-(D,L)-alanine (the sulfur analog of tryptophan) (S.G. Cady and M. Sono, *Arch. Biochem. Biophys.* 291, 326 (1991)), or 6-nitro-(D,L)-tryptophan. More preferably, the inhibitor of IDO comprises 1-methyl-(D)-tryptophan or 6-nitro-(D)-tryptophan.

5 Thus, the present invention describes a method of making antigen-presenting cells (APCs) for enhancing T-cell tolerance comprising the steps of:

- (a) isolating antigen-presenting cells (APCs) or their precursors (APC progenitors) from a first subject; and
- 10 (b) treating the isolated cells to select for APCs expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity sufficient to suppress proliferation of T cells (IDO<sup>+</sup> APCs).

The present invention also describes a method of making antigen-presenting cells (APCs) for enhancing T-cell activation in an individual comprising the steps of:

- 15 (a) isolating antigen-presenting cells (APCs) or their precursors (APC progenitors) from a subject; and
- (b) treating the isolated cells to select for APCs expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity not sufficient to cause suppression of T cell proliferation (IDO<sup>LO</sup> APCs).

20 As defined herein, isolated APCs or progenitor APCs comprise populations of cells which are either able to express high levels of IDO (IDO<sup>+</sup> APCs) or which constitutively express low levels of IDO (IDO<sup>LO</sup> APCs) as measured by protein levels (flow cytometry), mRNA levels, or T cell proliferation assays. The isolated APCs or APC progenitors may comprise mature blood-derived dendritic cells, mature tissue dendritic cells, monocyte-derived macrophages, non-dendritic APCs, B cells, plasma cells, or any mixture thereof. In 25 an embodiment, the isolated APCs or APC progenitors comprise a cell type bearing markers of antigen presentation and costimulatory function.

As defined herein, non-dendritic APCs comprise cells isolated directly from peripheral blood, bone marrow, or solid organ or tissue, or derived by *in vitro*culture of cells 30 from peripheral blood, bone marrow, or solid organ or tissue, which cells do not express CD83, but which do express high levels of MHC class II antigen as well as at least one marker of APC function. Such markers of APC function include, but are not limited to, CD80, CD86, and B7-H1 (Dong *et al.*, *Nature Med.*, 5: 1365-1369 (1999)). Such non-

dendritic APCs may express high constitutive or inducible levels of IDO (IDO<sup>+</sup>), low levels of IDO (IDO<sup>LO</sup>), or may comprise a mixture of IDO<sup>+</sup> and IDO<sup>LO</sup> cells. Non-dendritic APCs include, but are not limited to, endothelial cells, tissue macrophages, and other cells expressing constitutive or inducible MHC II.

5 Non-dendritic APC include cultured blood-derived non-dendritic APCs. As defined herein, cultured blood-derived non-dendritic APCs comprise isolated peripheral blood mononuclear cells or a fraction thereof which following culture *in vitro*, do not express CD83 but do express high levels of MHC class II antigens as well as one or more markers of APC co-stimulatory function, such as, but not limited to, CD80, CD86 or B7-H1 (Dong *et al.*,  
10 *Nature Med.*, 5: 1365-1369 (1999)), either constitutively or following exposure to maturation agents. Blood-derived non-dendritic APCs may be cultured in a medium with or without cytokines including, but not limited to, MCSF, GMCSF, IL4, IL3, IL 10, and TNF $\alpha$ . For example, in an embodiment, monocyte derived macrophages cultured in MCSF express high levels of IDO (IDO<sup>+</sup>) (Munn, D.H., *et al.*, *J. Exp. Med.*, 189: 1363-1372 (1999)). In another  
15 embodiment, CD14+/CD83- cells following culture in GMCSF + IL4 (which differentially adhere to plastic culture dishes) show no IDO mediated suppression (IDO<sup>LO</sup>).

As defined herein, dendritic cells (DCs) comprise cells isolated directly from peripheral blood, bone marrow, organs or tissues, or derived by culture of cells isolated from peripheral, bone marrow, organs, tissues, or isolated CD34 $^+$  stem cells collected from  
20 peripheral blood or bone marrow which cells express CD83 constitutively or following culture and maturation. DCs may be cultured in medium with or without cytokines, including, but not limited to GMCSF, IL4, IL3, and IL10.

Thus, as defined herein, immature dendritic cells (DCs) comprise DCs which express low levels of MHC class II antigens. As defined herein, low levels of MHC class II antigens are levels less than 2-fold greater than the negative control used in the assay to measure MHC class II antigen expression. Low levels of MHC class II may also be determined by comparison to mature DCs, and preferably comprise less than half the level of expression of MHC class II antigens found on mature DCs. MHC class II antigens may be measured by flow cytometry or other methods known in the art.

30 As defined herein, mature dendritic cells (DCs) comprise DCs which constitutively express high levels of MHC class II, or which have been treated with agents to cause maturation. As defined herein, high levels of MHC class II antigens are levels at least 2-fold greater than the negative control used in the assay to measure MHC class II antigen expression. Maturation can also be defined by comparison with the same population of DCs

prior to treatment with agents to induce maturation. Defined in this way, maturation comprises at least a 2-fold upregulation of MHC class II antigen. Agents causing maturation comprise TNF $\alpha$ , CD40-ligand (CD40L), activating anti-CD40 antibodies, cells engineered to express cell surface CD40-ligand, or bacterial or pathogen products.

5 As defined herein, B cells comprise cells isolated from blood, bone marrow, lymph nodes or other tissue which express one or more markers of B cell differentiation such as, but not limited to, CD19, CD20, CD21, or surface immunoglobulin, wherein B cell markers may be measured by flow cytometry or other methods known in the art.

10 As defined herein, plasma cells comprise cells isolated from blood, lymph node or other tissue which express CD38 and cytoplasmic immunoglobulin as measured by flow cytometry or other methods known in the art.

15 As defined herein, selection of APCs which comprise IDO $^+$  APCs or IDO $^{LO}$  APCs may comprise selective culturing of the cells, including a predetermined regimen of cytokines and/or maturation agents. For example, a cytokine cocktail such as those known in the art (Jonuleit, H., *et al.*, *Eur. J. Immunol.*, 27: 3135-3142 (1997)) may be employed. Thus, for selection of IDO $^+$  APCs or IDO $^{LO}$  APCs, cytokines may be combined singly, or added together with other agents used for the maturation of DCs (Jonuleit, H., *et al.*, *Eur. J. Immunol.*, 27: 315-3142 (1997); Reddy, A., *et al.*, *Blood* 90: 3640-3646 (1997)). Selection also comprises physical selection techniques such as selecting immunnosorting of either 20 IDO $^+$  or IDO $^{LO}$  cells. This is possible in that certain cell-surface antigens are associated with the IDO $^+$  and IDO $^{LO}$  phenotypes in APCs. In another embodiment, sorting comprises differential adherence of either IDO $^{LO}$  or IDO $^+$  cells to a substrate, presumably due to the expression of a specific cell surface marker that increases adherence.

25 T cell responses comprise allogeneic, xenogeneic, mitogen-driven, or antigen-driven responses. As defined herein, allogeneic T cells comprise T cells from a different individual of the same species, wherein such T cells proliferate in response to the presence of antigenic differences between the individuals. Xenogeneic T cells comprise T cells from an individual of a different species, wherein such T cells proliferate in response to the presence of antigenic differences between the species. As an example, T cells from a human recipient are 30 xenogeneic to a porcine tissue donor.

As defined herein, CD40-ligand (CD40L) comprises isolated polypeptides, multimers of such peptides, or other compositions that bind to the extracellular binding region of a CD40 receptor of human, porcine or other origin (e.g. U.S. patent 6,290,972, incorporated by reference in its entirety herein).

As defined herein, proinflammatory bacterial and pathogen products comprise materials isolated from bacteria or other pathogens, or synthetic compositions derived from compounds produced by such organisms, including, but not limited to, lipopolysaccharide, CpG DNA, or monophosphoryl lipid A, which have as their defining property that they cause up-regulation of MHC class II molecules and/or costimulatory molecules (CD80 or CD86) on immature dendritic cells or non-dendritic APCs.

Thus, the present invention relies on the discovery that APCs may express high levels of IDO ( $IDO^{+/POS}$ ) or low levels of IDO ( $IDO^{LO/NEG}$ ) depending upon their hematopoietic lineage or state of maturation including the effect of conditioning and/or licensing signals encountered during development. As an example, FIG. 1 summarizes a proposed 3-step model for the regulation of IDO in the specific case of monocyte-derived dendritic cell DC differentiation. In step 1, monocytes begin to differentiate along the DC lineage. Step 2 occurs during later DC differentiation and maturation, when there is a cryptic commitment of each individual DC to subsequently become either  $IDO^{+/POS}$  or  $IDO^{LO/NEG}$ . In an embodiment, those DCs that are negative for the cell surface marker CD123 commit to becoming IDO-negative ( $IDO^{LO/NEG}$ ), suggesting that there is some degree of inherent heterogeneity or “pre-commitment” within the circulating monocyte pool. In contrast, cells that are CD123 positive ( $CD123^+$ ) still have the option to become either functionally  $IDO^{+/POS}$  or  $IDO^{LO/NEG}$ , based on the conditions present during maturation. Thus, the  $CD123^+$  cells will commit to the  $IDO^{LO/NEG}$  (non-suppressor) phenotype if step 2 is driven solely by pro-inflammatory factors (e.g., CD40L, TNF $\alpha$ ). If counter-regulatory cytokines such IL10 or TGF $\beta$  are present during maturation, then the  $CD123^+$  cells will commit to the  $IDO^{+/POS}$  (suppressor) phenotype.

Although the cells are committed at step 2, the functional  $IDO^{+/POS}$  phenotype is not manifest until the DCs are activated, as for example, by the cytokine interferon $\gamma$  and possibly additional signals would come from the T cell during antigen presentation (step 3). Thus, although the same signal is delivered to both “non-suppressor” and “suppressor” DCs, the response of the DC to this signal, either IDO-mediated suppression of T-cell activation ( $IDO^{+/POS}$ ), or downregulation of IDO ( $IDO^{LO/NEG}$ ) such that the DC able to promote T-cell activation, depends on its history in step 2.

This model is consistent with existing models under which DCs undergo a “licensing” or “conditioning” process (corresponding to Step 2), either through direct cell-cell interaction with a helper T cell (Cella, M., *et al.*, *J. Exp. Med.*, **184**: 747-752 (1996); Ridge, J.P., *et al.*,

*Nature* 393: 474-478 (1998); Schoenberger, S.P., *et al.*, *Nature* 393: 480-483 (1998); Bennett, S.R., *et al.*, *Nature* 393: 478-480 (1998)) or via signals from the local cytokine milieu (Gallucci, S., *et al.*, *Nat. Med.* 5: 1249-1255 (1999); Kourilsky, P., *et al.*, *Trends in Immunol.*, 22: 502-509 (2001)). One of the previously undescribed aspects of DC maturation shown by the model in FIG. 1 is that DCs can be "licensed" to suppress, and that ability of DCs to become suppressive may be regulated *in vitro* by culture conditions. Additionally, the model teaches that suppressive and non-suppressive DC populations can be distinguished by 5 IDO expression (and cell surface markers associated with IDO<sup>+POS</sup> and/or IDO<sup>LO/NEG</sup> phenotypes). *In vivo*, the cytokines driving commitment to the suppressor phenotype (e.g., IL10, TGF $\beta$ ) may be provided by interaction with regulatory T cells (H. Waldmann and S. 10 Cobbold, *Immunity* 14: 399-406 (2001); Maloy, K.G., *et al.*, *Nature Immunol.*, 2: 816-822 (2001)) or may be present in a generalized tolerogenic milieu (Kourilsky, P. *et al.*, *Trends in Immunol.*, 22: 502-509 (2001); Fiocchi, C., *J. Clin. Invest.*, 108: 523-526 (2001); Chen, W. *et al.*, *Immunity* 22:14:715-725 (2001); Jonuleit, H. *et al.*, *Trends in Immunol* 22: 394-400 15 (2001)). *In vitro*, the regulatory cytokines may be supplied as recombinant cytokines during maturation.

Thus, the present invention teaches that this developmental scheme can be modeled *in vitro* to provide IDO<sup>+</sup> and IDO<sup>LO</sup> APCs. In humans, DC maturation has been associated with 20 improved antigen-presenting function (Dhodapkar, M.V., *et al.*, *J. Clin. Invest.* 105: R9-R14 (2000)) which as often been assumed to correspond to a loss of tolerogenic activity (Dhodapkar, M.V., *et al.*, *J. Exper. Med.*, 193: 233-238 (2001); Roncarolo, M.G. *et al.*, *J. Exp. Med.* 193: F5-F9 (2001)). However, maturation may not be associated with a loss of tolerogenic activity. Instead, tolerance may be related to an additional signal, as yet undescribed, and which is distinct from other antigen presentation and co-stimulatory factors 25 (Albert, M.L., *et al.*, *Nature Immunol.*, 2: 1010 (2001); Shortman, K., *et al.*, *Nature Immunol.*, 2: 988-989 (2001); T. Blankenstein and T. Shuler, *Trends Immunol.*, 23: 171-173 (2002)). The present invention teaches that this additional signal is the expression of IDO, such that mature DCs that express IDO will be tolerogenic and mature DCs that do not express IDO will be immunogenic.

30 Thus, the inventors believe that immature DCs are generally tolerogenic because in immature DCs, the activating population is ineffective, and therefore the tolerogenic population, although not optimized, is unopposed. The significant drawbacks to using immature DCs for therapy are that: (1) such cells constitute an uncharacterized mixture of

cells, and in many applications even a minor contaminating admixture of the undesired type of APC (*i.e.* immunogenic instead of tolerogenic) may render the APC population unusable or even harmful for the desired application; (2) immature DCs are inherently unstable and may mature (thus, providing an undesired and potentially activating population of cells); and 5 (3) immature DCs are inherently poor antigen-presenting cells due to their immature status, so the tolerogenic subset does not function as effectively as would a pure population of mature tolerogenic DCs.

The present invention therefore provides a method to produce relatively pure 10 populations of suppressive and nonsuppressive APCs. Most DCs and other APC populations contain a mixture of suppressive and nonsuppressive populations. The present invention teaches that the conditions under which the APCs are derived can markedly affect the ratio of tolerogenic APCs as compared to immunogenic APCs. Previously, the existence of different 15 tolerogenic and immunogenic subsets in humans could not be shown, nor was it possible to isolate specific tolerogenic (or immunogenic) subsets of APCs. Thus, the ability to use APCs for clinical applications was severely compromised as the presence of immunosuppressive 20 APCs in a preparation of cells being used to enhance the T cell response (*e.g.* an anti-tumor vaccine) would result in antagonism of the desired effect. Similarly, the presence of immunogenic APCs in a preparation of cells being used to suppress the T cell response (*e.g.* transplant therapy) would be counter-productive.

Referring now to FIG. 2, APCs may be treated by culturing under conditions to favor 25 production of (*i.e.* to select for) APCs that express high levels of IDO (IDO<sup>+</sup> APCs). In an embodiment, the isolated cells are cultured in medium which is essentially free of serum. Alternatively (or additionally), the cells may be cultured in the presence of macrophage colony stimulating factor (MCSF) or granulocyte-macrophage colony stimulating factor (GMCSF). When GMCSF is used, the concentration may range from 10 ng/ml to 1000 30 ng/ml, or more preferably from 50 ng/ml to 500 ng/ml. Alternatively (or additionally), the cells may be cultured in the presence of cytokines such as, but not limited to, TGF $\beta$ , IL10, IL4, IL3, or any combinations thereof.

In an embodiment, the cells are also be treated with an agent to cause maturation of 35 those APCs that express high levels of IDO. Preferably, the maturation agents comprise TNF $\alpha$ , IL10, TGF $\beta$ , CD40-ligand, activating anti-CD40 antibodies, cells engineered to express cell surface CD40-ligand, proinflammatory bacterial or pathogen products, or any combination thereof. Thus, these agents may be combined singly, or added together with

other agents used for the maturation of DCs (Jonuleit, H., *et al.*, *Eur. J. Immunol.*, 27: 3135-3142 (1997); Reddy, *et al.*, *Blood* 90: 3640-3646 (1997)).

Following culture and maturation steps, further purification can be accomplished by differential adherence to a selected substrate chosen and optimized to yield preferential enrichment of the desired IDO<sup>+</sup> population, by methods described herein. Alternatively (or 5 additionally), the purity of the IDO<sup>+</sup> population is increased by immunosorting based on cell-surface antigens that associate with IDO<sup>+</sup> APCs. For example, in an embodiment, CD123 and CCR6 are associated with IDO<sup>+</sup> APCs and CD14 is associated with IDO<sup>LO</sup> APCs. Thus, the present invention contemplates that IDO<sup>+</sup> APCs isolated directly from tissues may only 10 require maturation and immunosorting to comprise a pure population. Alternatively, when using CD34<sup>+</sup> APC progenitors, culture may be required for differentiation, and the cytokines chosen for use during culture are selected based on their ability to increase the IDO<sup>+</sup> population.

FIG. 2 also shows that APCs may be treated by culturing under conditions to favor 15 production of APCs that express low levels of IDO (IDO<sup>LO</sup> APCs). For example, cells may be cultured in the presence of GMCSF + IL4 and then matured in the presence of TNF $\alpha$  and CD40 ligand. In an embodiment, APCs are cultured in the presence of neutralizing antibodies to IL10 and TGF $\beta$ . The cells may also be treated with an agent to cause 20 maturation of those APCs that express low levels of IDO. Preferably, the maturation agents comprise TNF $\alpha$ , CD40-ligand, activating anti-CD40 antibodies, cells engineered to express cell-surface CD40-ligand, proinflammatory bacterial or pathogen products, or any 25 combination thereof. Thus, these agents may be combined singly, or added together with other agents used for the maturation of DCs (Jonuleit, H., *et al.*, *Eur. J. Immunol.*, 27: 3135-3142 (1997); Reddy, *et al.*, *Blood* 90: 3640-3646 (1997)).

As described above, and referring now to FIG. 3, the present invention further 25 includes the step of measuring expression of at least one cell surface antigenic marker that identifies the cells as expressing high levels of IDO (IDO<sup>+</sup> APCs) or not expressing high levels of IDO (IDO<sup>LO</sup> APCs). Preferably, the absence or presence of the cell surface marker associated with high IDO is used to select for, and isolate, APCs that express high levels of 30 IDO (IDO<sup>+</sup> APCs) from APCs that do not express high levels of IDO (IDO<sup>LO</sup> APCs). For example, markers associated with high levels of IDO in APCs comprise CD123 and CCR6. A less preferred marker is CD11c. In an embodiment, the presence of a cell-surface marker associated with low levels of IDO expression (IDOLO) is used to deplete the preparation of non-tolerogenic cells. Preferably, a marker associated with low levels of IDO in APCs is

CD14. For example, in an embodiment, monocytes may be treated with a cytokine cocktail to induce differentiation and expression of IDO. The cells which express high levels of IDO, and are tolerance-inducing, are then separated from those cells which do not express IDO using at least one cell surface marker which shows a correspondence with IDO expression.

5 In another embodiment, the expression of uncharacterized cell surface proteins is used to facilitate separation of IDO<sup>+</sup> cells from IDO<sup>LO</sup> APCs. For example, in an embodiment, cells cultured in serum-free medium display enhanced adherence of the IDO<sup>LO</sup> APCs to the plastic culture dish. Thus, by selecting those cells which do not adhere to the plastic dish, a population of IDO<sup>+</sup> cells is selected.

10 For example, and referring now to FIG. 4, DCs (immature) cultured in serum-free medium and enriched by non-adherence of IDO<sup>+</sup> cells to plastic culture wells (*i.e.* the IDO<sup>LO</sup> cells adhere) show moderate suppression of allogeneic T cell proliferation when still immature (FIG. 4A). Suppression may be measured as the finding more APCs (*i.e.* a low T cell:APC ratio) results in less T cell proliferation (FIG. 4A). Preferably, the inhibition is 15 substantially due to IDO expression, as evidenced by reversal of the inhibition by 1-methyl-(D)-tryptophan (1-MT), an inhibitor of IDO. In contrast, mature DCs exhibit a much higher level of suppression, with suppression occurring even at T cell : APC ratios of 100:1 (FIG. 4B and 4C). Addition of 1-MT (to inhibit IDO mediated suppression) causes a significant increase in T cell proliferation, to levels greater than immature DCs. Thus, contrary to 20 current models, using the methods of the present invention, maturation actually enhances the suppression of T cells, and the enhanced suppression is due to IDO.

Referring now to FIG. 5, cultured blood-derived APCs derived in bovine serum based medium (and not fractionated by differential adherence) produce a preparation comprising a mixture of IDO<sup>+</sup> and IDO<sup>LO</sup> cells. In an embodiment, a population of immature DCs which 25 express the cell surface marker CD123 (CD123+) constitutively express immunoreactive IDO protein (FIG. 5A and C for myeloid DCs derived in GMCSF + IL4; FIG. 5B for macrophages derived in MCSF, respectively). Maturation for 2 days with TNF $\alpha$ , or with CD40L, or with a published cocktail of cytokines (Jonuleit H., *et al.*, *Eur. J. Immunol.*, 27: 3135-3142 (1997), or monocyte-condition medium (Reddy *et al.*, *Blood* 90: 3640-3646 (1997)) does not affect 30 IDO expression in the subset of CD123+ cells (not shown). In an embodiment, CD123 positive (CD123<sup>+</sup>) cells expressing high levels of IDO (IDO<sup>+</sup>) also express high levels of the cytokine receptor CCR6 (FIG. 5C). In contrast, cells selected as adhering to the culture dishes comprise primarily IDO<sup>LO</sup> non-dendritic APCs. Preferably, expression of IDO

protein correlates with the ability of the cells to stimulate T cell proliferation as measured by tritiated thymidine incorporation into T cell DNA (FIG. 5E).

Association of Cell Surface Markers with IDO Expression

5 Because IDO is an intracellular enzyme, expression of the enzyme is not easy to detect in the intact (*i.e.* living) cell. Thus, the present invention utilizes the discovery that specific cell surface markers are associated with expression of IDO in antigen-presenting cells (FIG. 3).

10 For markers associated with cells having high levels of IDO expression (IDO<sup>+</sup>), the marker preferably comprises a cell surface protein (antigen) for which greater than 75% of the cells express high levels of IDO by flow cytometry or suppression of T cell proliferation as measured using T cell proliferation assays, and more preferably, for which greater than 90% of the cells express high levels of IDO by flow cytometry or suppression of T cell proliferation as measured using T cell proliferation assays, and even more preferably, for 15 which greater than 95% of the cells express high levels of IDO by flow cytometry or suppression of T cell proliferation as measured using T cell proliferation assays.

In an embodiment, the cell surface marker associated with IDO expression is CD123. CD123 (the IL3-receptor  $\alpha$  chain) is expressed on the small population of lymphoid-lineage “plasmacytoid” dendritic cells in peripheral blood (Liu, Y. J., *Cell*, **106**: 259-262 (2001)), but 20 it is also expressed at lower levels on a poorly-defined subset of myeloid-lineage dendritic cells *in vivo* (Olweus, J., *et al.*, *Proc. Natl. Acad. Sci., USA*, **94**: 12551-12556 (1997); Summers, K.L., *et al.*, *Am. J. Pathol.*, **159**: 285-295 (2001)).

25 Referring now to FIG. 5, preferably there is a 1:1 correspondence between APCs expressing IDO (IDO<sup>+</sup>) and at least one cell surface marker. For example, in an embodiment, monocyte-derived DCs cultured for 7 days in GMCSF + IL4 (FIG. 5A) or macrophage-derived DCs cultured in MCSF (FIG. 5B) display a discrete subset of cells that express high levels of IDO (IDO<sup>+</sup>), and express the cell surface marker CD123 (FIGS. 5A and B).

30 In addition, other cell surface markers may be used to identify IDO<sup>+</sup> cells. Thus, in an embodiment, a majority of IDO<sup>+</sup> APCs express the myeloid-lineage marker CD11c (FIG. 5A and B).

Preferably, another marker highly associated with IDO expression is the chemokine receptor CCR6. CCR6 is the receptor for the chemokine mip-3 $\alpha$ , a chemotactic factor for immature dendritic cells (Yang, D., *et al.*, *J. Immunol.*, **163**: 1737-1741 (1999)). Different

subsets of dendritic cells express distinct patterns of chemokine receptors (Sozzani, S., *et al.*, *J. Leukocyte Biol.* 66: 1-9 (1999)). CCR6 is expressed on CD34<sup>+</sup>-derived dendritic cells at immature stages of differentiation, and on immature monocyte-derived dendritic cells cultured with transforming growth factor (TGF)- $\beta$ , but is lost under some conditions when 5 dendritic cells mature (Yang, D., *et al.*, *J. Immunol.* 163: 1737-1741 (1999)). The present invention shows that under conditions favoring high expression of IDO, over 90% of APCs which express IDO also express CCR6 (FIG. 5C). Thus, IDO-expressing, tolerance-inducing APCs may comprise the cell surface markers CD123, CCR6, and in some cases, CD11c.

10 The specific pattern of markers that identifies the IDO<sup>+</sup> (or IDO<sup>LO</sup>) population varies depending on the conditions used to isolate and culture the APCs. For example, CD11c is expressed at low levels in IDO<sup>LO</sup> cells cultured in bovine calf serum based medium (high seeding density and no differential adherence selection; FIG. 5A) but is expressed at higher levels for the IDO<sup>LO</sup> culture in serum-free medium (low seeding density and a final fractionation by differential adherence of non-dendritic APCs to the culture dish).

15 In an embodiment, enrichment using the cell surface marker alters the composition of the preparation such that it displays a higher level of IDO activity as measured by suppression of a T cell proliferation assay (e.g. an allogenic MLR). For example, and referring now to FIG. 6, CD123 enriched (CD123<sup>+</sup>) APCs are markedly less efficient at stimulating T-cell proliferation than either the original unfractionated mixture, or the CD123 20 depleted subset (CD123<sup>LO</sup>) that remains after sorting. The lack of T-cell activation is due to IDO expression, as shown by the ability of the IDO inhibitor, 1-methyl-(D,L)-tryptophan (1-MT), to prevent suppression. Thus, addition of 1-MT allowed the APCs to stimulate T-cell proliferation at near control levels, indicating that IDO is involved in the suppression. Enrichment may be accomplished by positive selection using magnetic beads comprising 25 antibodies to the marker of interest, adhesion, flow cytometric sorting or other selections techniques known in the art.

30 Alternatively, when a pure population of IDO<sup>+</sup> APCs are desired, cell sorting techniques may be used to generate a population of APCs depleted of IDO<sup>LO</sup> cells using a cell surface antigen that correlates with low levels of IDO expression. Preferably, the cell surface antigen is a marker for which greater than 75% of the antigen-bearing cells do not express high levels of IDO by flow cytometry or suppression of T cell proliferation assays, more preferably, greater than 90% of the antigen-bearing cells do not express high levels of IDO by flow cytometry or suppression of T cell proliferation assays, and even more preferably,

greater than 95% of the antigen-bearing cells do not express high levels of IDO by flow cytometry or suppression of T cell proliferation assays.

In an embodiment, the marker associated with IDO<sup>LO</sup> cells comprises CD14. CD14 (the endotoxin-binding protein receptor) is a well-accepted marker for cells of the monocyte-macrophage lineage (Szabolcs, P., *et al.*, *Blood* 87: 4520-30 (1996)). Monocyte-derived dendritic cells down-regulate CD14 to undetectable (background) levels when they differentiate along the dendritic cell lineage (Pickl, W.F., *et al.*, *J. Immunol.* 157: 3850-3859 (1996)). Mature myeloid dendritic cells do not express CD14 (K. Shortman and Y.-J. Liu, *Nature Reviews: Immunology* 2: 151-161 (2002)). Thus, in a culture comprising both mature DCs and a second population of non-dendritic APCs expressing CD14, the expression of CD14 can be used to distinguish between the two populations.

Thus, in yet an embodiment, a population of cells comprising low levels of IDO expression (IDO<sup>LO</sup>) is generated by depleting the APCs of IDO<sup>+</sup> APCs (e.g. by selection with CD123 or other markers associated with high IDO) or by positive selection for markers associated with low IDO expression, such as CD14.

In yet another embodiment, the expression of uncharacterized cell surface proteins is used to facilitate separation of IDO<sup>+</sup> cells from IDO<sup>LO</sup> cells. For example, cells cultured in serum-free medium display enhanced adherence of the IDO<sup>LO</sup> APCs to the plastic culture dish. Thus, by selecting those cells which do not adhere to the plastic dish, a population of IDO<sup>+</sup> cells is selected. Examples of substrates which may be used for selection of cells by adherence include, but is not limited to, plastic (for example, plastic culture flasks or petri dishes), plastic treated by chemical or other means to facilitate adherence of tissue culture cells (tissue culture plastic), gas-permeable collection bags used in isolation and storage of blood products, filters, protein coatings, protein-lipid films and the like.

For example, FIG. 5D shows adherent cells taken from culture of monocytes in serum-free medium supplemented with GMCSF +IL4 and matured with a cocktail of TNF $\alpha$ , IL1 $\beta$ , IL6 and PGE2 as previously described (Jonuleit, H. *et al.*, *Eur. J. Immunol.*, 27: 3135-3142 (1997)). In this type of culture, the adherent cells are normally discarded because they are not dendritic cells (Jonuleit, H., *et al.*, *Eur. J. Immunol.*, 27: 3135-3142 (1997); Reddy, A., *et al.*, *Blood* 90: 3640-3546 (1997)). These cells are in fact quite valuable, as they represent a substantially purified preparation of IDO<sup>LO</sup> cells. These cells are not IDO<sup>+</sup>, but they express markers of APC function (MHC class II, CD80, and CD86) at levels similar to non-adherent (IDO<sup>+</sup>) cells from the same cultures. Greater than 95% of the IDO<sup>LO</sup> adherent

cells express CD14, whereas less than 10% of the IDO<sup>LO</sup> adherent cells express CD 123 or CCCR6.

*IDO<sup>+</sup> APCs as Transplant Therapeutics*

5 Cells which are tolerance-inducing APCs (IDO<sup>+</sup> APCs), may be used to promote tolerance in a subject. Thus, the invention comprises a method of preparing cells comprising tolerance-inducing APCs and the use of the cells to enhance immunological tolerance in an individual.

10 Thus, in one aspect, the present invention comprises a method to generate APCs for enhancing T cell tolerance towards cells, tissues and specific antigens in an individual comprising administration of a cell preparation in which the antigen-presenting cells (APCs) express high levels of IDO. In this aspect, the present invention relies on the discovery that APCs expressing high levels of IDO (IDO<sup>+</sup>) are associated with reduced ability to activate T-cells (FIG. 6). In this way, IDO<sup>+</sup> APCs are used to increase the likelihood of acceptance of a 15 graft or transplant from a first donor mammal to a second recipient mammal.

Thus, in one aspect, the present invention comprises a method for enhancing tolerance in a subject comprising the steps of:

- (a) isolating antigen-presenting cells (APCs) or their precursors (APC progenitors) from a first subject;
- 20 (b) treating the cells to select for APCs that express levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity sufficient to suppress proliferation of T cells (IDO<sup>+</sup> APCs); and
- 25 (c) administering the treated cells back to the original subject or to a second subject in an amount effective to generate a tolerance-promoting response in the recipient subject.

30 In an embodiment, a tolerance-promoting response reduces T-cell activation in the recipient subject. In an embodiment, the tolerance-promoting response prolongs the survival of transplanted cells or tissues in the recipient subject. In yet another embodiment, the treated cells are administered back to the original subject, and the tolerance-promoting response reduces the symptoms of an autoimmune disease in the subject.

As described herein, the present invention also comprises compositions for enhancing T cell tolerance. For example, such compositions may be used to promote acceptance of a tissue transplant or graft. Thus, the present invention also comprises a composition for enhancing T cell tolerance comprising antigen-presenting cells (APCs) selected as

comprising APCs expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity sufficient to suppress proliferation of T cells (IDO<sup>+</sup> APCs). In one aspect, the compositions are made by the methods of the present invention.

5 In an embodiment, IDO<sup>+</sup> APCs of the methods and compositions of the present invention are evaluated by measurement of the number of cells expressing IDO. Preferably, the tolerance-inducing IDO<sup>+</sup> APCs comprise a cell population wherein at least 90% APCs expressing IDO at levels at least 2-fold greater than background, and more preferably at least 95% of the APCs express IDO at levels at least 2-fold greater than background, where background comprises a negative control for IDO.

10 Alternatively or additionally, IDO activity is quantified using a biological assay. In an embodiment, the tolerance-inducing IDO<sup>+</sup> APCs comprise suppression of T cell proliferation comprising at least a 2-fold increase in T cell proliferation in the presence of an IDO inhibitor as compared to T cell proliferation in the absence of an IDO inhibitor.

15 Preferably, the inhibitors comprise 1-methyl-(D,L)-tryptophan,  $\beta$ -(3-benzofuranyl)-(D,L)-alanine,  $\beta$ -[3-benzo(b)thienyl]-(D,L)-alanine, or 6-nitro-(D,L)-tryptophan. More preferably, the inhibitors comprises 1-methyl-(D)-tryptophan or 6-nitro-(D)-tryptophan.

20 Preferably, the isolated APCs of the methods and compositions of the present invention comprise non-dendritic APCs, mature blood-derived dendritic cells, mature tissue dendritic cells, monocyte-derived macrophages, non-dendritic cells, B cells, plasma cells, or any mixture thereof. Also preferably, the APCs comprise markers of antigen presentation and co-stimulatory function. Preferably, the APCs are isolated from peripheral blood, bone marrow, lymph nodes or a solid organ from a mammal. More preferably, the subject is human.

25 One object of the present invention is to develop tolerance-promoting APCs that present a specific subset of antigens of interest. For example, tolerance-promoting APCs that present antigens from a donor may be administered to a transplant recipient to promote acceptance of a graft or transplant. Thus, in an embodiment, the subject from which the APCs or APC progenitors of the methods and compositions of the present invention are isolated comprises a tissue donor to a second subject. In another embodiment, the APCs or 30 APC progenitors are isolated from a subject with an autoimmune disorder for subsequent preparation of IDO<sup>+</sup> APCs for use in treating the disorder.

35 Alternatively, the treated APCs of the methods and compositions of the present invention are exposed to at least one source of antigen after isolation from a first subject and

selection as  $\text{IDO}^+$  APCs. Preferably, the source of antigen comprises antigens expressed by a donor tissue graft. Also preferably, the source of antigen comprises protein or other material to which a patient has an autoimmune disorder (see e.g. Yoon, J.-W., *et al.*, *Science* **284**: 1183-1187 (1999) for examples of such proteins). Thus, in an embodiment, the subject from 5 which the APCs or progenitor APCs are isolated comprises a patient with an autoimmune disorder. In an embodiment, the antigen comprises a purified, or a synthetic or recombinant polypeptide representing a specific antigen to which it is desired that tolerance be induced, or a short synthetic polypeptide fragment derived from the amino acid sequence of such an antigen. In an embodiment, the isolated APCs are transfected or genetically engineered to 10 express at least one antigenic polypeptide (see e.g. Nair, S.K., *et al.*, *Int. J. Cancer* **82**: 121-124 (1999); Heiser, A., *et al.*, *J. Clin. Invest.*, **109**: 409-417 (2002)).

In an embodiment, selection of  $\text{IDO}^+$  cells of the methods and compositions of the present invention is facilitated using a cell surface marker that identifies the cells as expressing levels of IDO sufficient to suppress T cell proliferation ( $\text{IDO}^+$  APCs) or 15 expressing levels of IDO not sufficient to suppress T cell proliferation ( $\text{IDO}^{\text{LO}}$  APCs) as described herein. The markers used may include, but are not limited to, CD123, CCR6, CD11c, CD14, or any combination thereof. Alternatively, the method may include differential adhesion to a substrate to separate APCs that express low levels of IDO ( $\text{IDO}^{\text{LO}}$  APCs) from APCs that express high levels of IDO ( $\text{IDO}^+$  APCs).

20 In an embodiment, the composition used to enhance T cell tolerance may include a pharmaceutically acceptable carrier. Alternatively, the composition may include one or more immunosuppressive pharmaceuticals in a unit dosage form.

As defined herein, a graft is a tissue specimen for transplantation from one mammal 25 into another mammal. A host mammal is defined as the recipient of a graft specimen from a donor mammal, wherein the donor mammal and the host mammal are distinct entities. The grafts may either be homografts (a graft transplanted between mammals of the same species) or xenografts (a graft transplanted between mammals of the different species).

Isolation of mammalian cells for use as APCs of the present invention may be 30 accomplished in accordance with the methods described in the Examples below. In addition, U.S. Patent Nos. 5,849,589, 6,008,004, 6,194,204, and 6,274,378 describe isolation of mixed populations (*i.e.* not selected as tolerance-inducing) dendritic cells for use with the selection methods described herein and are hereby incorporated by reference in their entirety. Thus U.S. Patent 5,849,589 describes a method to induce differentiation of a monocyte into a dendritic cell (DC); U.S. Patent No. 6,008,004 describes a DC precursor found among bone

marrow CD34<sup>+</sup> cells; U.S. Patent No. 6,194,204 describes a serial separation technique for isolating DC from peripheral blood; and U.S. Patent No. 6,274,378 describes a method to increase the yield of DCs by culturing in GMCSF and IL-4. Those skilled in the art would be able to implement modifications to the disclosed methods of isolating cells for propagation as 5 APCs without the exercise of undue experimentation.

U.S. Patent Nos. 5,871,728 and 6,224,859, the disclosure of which is incorporated by reference in full herein, describe the isolation of dendritic cells from a donor for use in a transplant regimen. In contrast to the present invention, however, the dendritic cells in U.S. 10 5,871,728 and 6,224,859 B1 are cultured under conditions to remain in an immature state and therefore do not present DCs which are optimized to promote a tolerogenic response, nor are they purified to enrich for the tolerogenic population and/or the immunogenic population.

In an embodiment, autologous tolerogenic APCs are pulsed with an autoantigen (*i.e.* a protein or other material to which a patient has developed an autoimmune immunologic response as part of an autoimmune disorder) and administered back to a patient with an 15 autoimmune disease. In another embodiment, tolerogenic APCs are isolated from the donor of a bone marrow transplant or hematopoietic stem-cell transplant and administered to a second subject who is receiving the transplant so as to prevent graft-versus-host disease in the recipient subject. Alternatively administration of tolerogenic APCs may be used to treat established graft-versus-host disease in a transplant recipient. In both cases, the goal is to 20 initiate the development of a regulatory T cell response to a target antigen or set of antigens which will reduce the autoimmune or graft-versus-host T cell responses (H. Waldmann and S. Cobbold, *Immunity* 14: 399-406 (2001)).

Tolerogenic APCs may be administered prior to transplantation. In an embodiment, prophylactic administration may be commenced as early as 1 month prior to transplantation, 25 and more preferably at about 1 week prior to transplantation. Alternatively, or additionally, administration may be at the time of transplantation and for several months following the transplantation, and at least several weeks following the transplantation, or even more preferably, several days following transplantation.

Immunosuppressive agents may also be included as part of the transplant regimen. 30 Immunosuppressive reagents are typically administered at the time of transplantation and at least daily for some period afterwards. The amount of immunosuppressive agent is preferably adjusted based upon the success of the cell-driven response (*i.e.* the response as a result of administration of IDO<sup>+</sup> APCs.)

Pharmaceutical formulations can be prepared by procedures known in the art. For example, the compounds can be formulated with common excipients, diluents (such as phosphate buffered saline), tissue-culture medium, or carriers (such as autologous plasma or human serum albumin) and administered as a suspension.

5 The invention contemplates methods of administration which are well known in the art. Administration of the APCs of the present invention may include, but is not limited to, intravenous, subcutaneous, and intra-tumoral modes of administration. Additionally, the compounds are well suited to formulation as sustained release dosage forms of at least part of the preparation (e.g. immunosuppressive agents). Preferably, the cells are administered in a 10 dose ranging from  $5 \times 10^5$  to  $5 \times 10^{10}$  cells per dose. More preferably, the cells are administered in a dose ranging from  $5 \times 10^6$  to  $5 \times 10^9$  cells per dose. Even more preferably, the cells are administered in a dose ranging from  $5 \times 10^7$  to  $1 \times 10^8$  cells per dose.

15 *IDO<sup>LO</sup> APCs as Immunogenic Vaccines*

15 The present invention also provides a means to isolate cells enriched for immunostimulatory APCs that show enhanced T-cell activation. For example, cells depleted of tolerance-inducing APCs can be used as anti-cancer vaccines or anti-viral vaccines to increase the host response to cancer or viral antigens, respectively.

20 In this aspect, the present invention comprises a method for increasing the protective immune response to at least one specified antigen in a subject comprising the steps of:

- (a) isolating antigen-presenting cells (APCs) or their precursors (APC progenitors) from a subject;
- (b) treating the cells to select for APCs expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity not sufficient to cause suppression of T cell proliferation (IDO<sup>LO</sup> APCs); and
- (c) administering the treated cells back to the subject in an amount effective to generate a protective immune response in said subject.

25 In an embodiment, a protective immune response comprises a reduction in size of a tumor or a reduction in the clinical progression of a malignancy. In another embodiment, a protective immune response is associated with increased resistance to at least one pathogen. For example, such increased resistance to a pathogen may comprise an increased resistance to infection, a reduced pathogen load, or increased production of pathogen specific antibodies or T cells.

The present invention also comprises compositions for increasing T cell activation. Such compositions are useful for generating a protective immune response. Thus in another aspect the present invention comprises isolated antigen-presenting cells selected as comprising APCs expressing low levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity (IDO<sup>LO</sup>), wherein the IDO<sup>LO</sup> cells comprise a population of APCs expressing IDO at a level not sufficient to cause suppression of T cell proliferation (IDO<sup>LO</sup> APCs). The IDO<sup>LO</sup> APCs may be prepared by the methods described in the present invention or other methods known in the art.

Preferably, IDO<sup>LO</sup> cells of the methods and compositions of the present invention comprise a population of APCs having less than 10% of the population expressing IDO at a level of greater than 2-fold over background. More preferably, IDO<sup>LO</sup> cells of the methods and compositions of the present invention comprise a population of APCs having less than 5% of the population expressing IDO at a level of greater than 2-fold over background. Also preferably, IDO<sup>LO</sup> APCs comprise non-suppressor activity quantified by a mixed leukocyte reaction as less than 1.5 fold increase in T cell proliferation in the absence of an IDO inhibitor as compared to T cell proliferation in the presence of an IDO inhibitor. Preferably, the IDO inhibitors comprise 1-methyl-(D,L)-tryptophan,  $\beta$ -(3-benzofuranyl)-(D,L)-alanine,  $\beta$ -[3-benzo(b)thienyl]-(D,L)-alanine, or 6-nitro-(DL)-tryptophan. Also preferably, the IDO inhibitors comprise 1-methyl-(D)-tryptophan or 6-nitro-(D)-tryptophan.

Preferably, the isolated APCs or progenitor APCs comprise mature blood-derived dendritic cells, mature tissue dendritic cells, monocyte-derived macrophages, non-dendritic APCs, B cells, plasma cells, or any mixture thereof. Also preferably, the isolated APCs progenitor APCs comprise a cell type bearing markers of antigen presentation and costimulatory function. Also, in preferred embodiments, the APCs progenitor APCs are isolated from peripheral blood, bone marrow, lymph nodes or a solid organ from a human or other mammal.

In an embodiment the treated APCs of the methods and compositions of the present invention are exposed to at least one source of antigen after isolation from a subject and selection as IDO<sup>LO</sup> APCs. Preferably, the antigen is a polypeptide expressed by a tumor. Alternatively, the antigen may be expressed by a pathogen. Preferably, the antigen comprises an unpurified tumor or viral preparation. In another embodiment, the antigen is a synthetic or recombinant protein representing a known antigen to which it is desired to induce an immune response, or a short synthetic polypeptide derived from the amino acid sequence of such a

protein. In another embodiment, the APCs selected as IDO<sup>LO</sup> are transfected or genetically engineered to express at least one such antigenic protein or polypeptide.

In an embodiment, selection of IDO<sup>LO</sup> cells of the methods and compositions of the present invention is facilitated using a cell surface marker that identifies the cells as expressing high levels of IDO (IDO<sup>+</sup> APCs) or not expressing high levels of IDO (IDO<sup>LO</sup> APCs) as described herein. The markers used may include, but are not limited to CD123, CD11c, CCR6, CD14, or any combination thereof. Alternatively, the method may include differential adhesion to a substrate to separate APCs that express low levels of IDO (IDO<sup>LO</sup> APCs) from APCs that express high levels of IDO (IDO<sup>+</sup> APCs).

As described herein, the APCs selected as IDO<sup>LO</sup> APCs of the methods and compositions of the present invention may be exposed to at least source of antigen after isolation from said first subject. Preferably, the antigen is a polypeptide expressed by a tumor. Alternatively, the antigen may be expressed by a pathogen. For example, U.S. Patent Nos. 6,228,640, 6,210,662, 6,080,409, 5,994,126, 5,851,756, and 5,582,831 describe the manipulation of isolated dendritic cells to produce immunostimulatory vaccines specific to certain antigens. The disclosures of U.S. Patent Nos. 6,228,640, 6,210,662, 6,080,409, 5,994,126, 5,851,756, and 5,582,831 are hereby incorporated in full by reference.

Alternatively, the isolated APCs are transfected or genetically engineered to express at least one antigenic polypeptide (see e.g. Nair, S.K., *et al.*, *Int. J. Cancer*, 82: 121-124 (1999); Heiser, A., *et al.*, *J. Clin. Invest.*, 109: 409-417 (2002))

Antigens may also be physically introduced into cells. For example, U.S. Patent No. 6,228,640 BI describes pulsing DCs with tumor RNA or expression products to prepare APCs comprising expression of specific antigens. Also, U.S. Patent Nos. 6,210,662 and 6,080,409 describe methods and compositions generated by activating APCs by contact with a polypeptide complex constructed by joining together a dendritic cell-binding protein (GMCSF) and a polypeptide antigen. U.S. Patent Nos. 5,994,126 and 5,851,756 describes a method for producing mature DCs pulsed with antigen, including particulates where the antigenic material is expressed on the surface of the cells as immunogens for vaccines. U.S. Patent No. 5,582,831 describes formulation of tumor vaccines by exposing tumor cells to a cross-linking agent to generate antigenic protein complexes.

In an embodiment, the isolated APCs of the methods and compositions of the present invention further comprise at least one cell surface antigenic marker that identifies the cells as expressing low levels of IDO (IDO<sup>LO</sup> APCs) or expressing high levels of IDO (IDO<sup>+</sup> APCs). The marker may include, but is not limited to CD123, CD11c, CCR6, or any combination

thereof. Alternatively, the method may include differential adhesion to a substrate to separate APCs that express low levels of IDO (IDO<sup>LO</sup> APCs) from APCs that express high levels of IDO (IDO<sup>+</sup> APCs).

5 The compositions comprising IDO<sup>LO</sup> APCs may also include a pharmaceutically acceptable carrier, where pharmaceutically acceptable carriers include, but are not limited to the carriers described herein.

*Methods and Kits to Measure the Amount of Immunosuppressive Cells in a Mixed Population of APCs*

10 The present invention also describes methods to quantitate the levels of immunosuppressive APCs in a population of APCs. For most applications it would be preferable, if not absolutely required, to determine the nature of the cell population being used. For example, when utilizing a preparation of cells for inducing tolerance in a host, a level of contaminating IDO<sup>LO</sup> cells of less than 10%, and more preferably less than 5%, is 15 desired. Conversely, when utilizing a preparation of cells for increasing the immune response in a host, the level of contaminating IDO<sup>+</sup> cells should be determined.

20 Thus, in one aspect, the present invention comprises a method to determine the number of tolerance-inducing antigen-presenting cells (APCs) in a cell population comprising measuring the number of cells expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme sufficient to suppress proliferation of T cells (IDO<sup>+</sup> APCs) in the cell population. In an embodiment, IDO is quantified on a cell-by-cell basis. In an embodiment, IDO is quantified in a bulk population of APCs.

25 In another aspect, the present invention comprises a kit for determining the number of tolerance-inducing antigen-presenting cells (IDO<sup>+</sup> APCs) in a cell population comprising reagents to measure levels of indoleamine 2,3-dioxygenase (IDO) enzyme in the APCs, wherein the reagents are packaged in at least one individual container.

30 The immunosuppressive IDO<sup>+</sup> APCs may also be quantified using a biological assay. Thus, in another aspect, the present invention comprises a method to quantify the ability of a population of APCs to suppress T cell proliferation comprising measuring the ability of the cell population to increase in T cell proliferation in the presence of an IDO inhibitor as compared to in the absence of an IDO inhibitor. The present invention also comprises a kit for determining the ability of a population of APCs to suppress T cell proliferation comprising an IDO inhibitor packaged in at least one individual container. In an

embodiment, the kit includes individual assay vessels which provide a pre-determined cell density. Preferably, the assay vessels comprise round-bottomed or V-shaped wells.

*IDO<sup>+</sup> APCs and mip-3 $\alpha$  as Markers of Tumors*

5        Because tolerance-inducing APCs reduce the host's ability to reject foreign antigens which are present on tumor cells, the presence of tolerance-inducing APCs in a tumor is associated with a less favorable prognosis than in cases where tolerance-inducing APCs are not present. Thus, the present invention also describes assessing the relative risk of tumor progression by assaying tissue from a tumor or tumor draining lymph node for antigen-presenting cells of myeloid-lineage which have high levels of expression of the intracellular enzyme indoleamine 2,3-dioxygenase (IDO).

10

Thus, in another aspect, the present invention comprises a method for assessing the relative risk of tumor progression in a subject comprising the steps of:

15        (a) assaying a sample of tissue from a tumor or tumor draining lymph node from a subject for expression of the enzyme indoleamine 2,3-dioxygenase (IDO); and

      (b) correlating the risk of tumor progression to IDO expression in the tissue sample, wherein IDO expression is positively correlated with an increase in the risk of tumor progression.

20        In an embodiment, the method further includes identification of cell surface markers associated with high IDO expression. Preferably, the cell surface markers comprise CD123, CD11c or CCR6.

25        The present invention also comprises kits for assessing the relative risk of tumor progression in a subject. For example, in one aspect, the present invention comprises a kit for assessing the relative risk of tumor progression in a subject comprising reagents for detection of the enzyme indoleamine 2,3-dioxygenase (IDO) in a sample of tissue from a tumor or tumor draining lymph node from a subject, wherein the reagents are packaged in at least one individual container. Preferably, the kit further comprises reagents for detection of cell surface or immunohistochemical markers associated with high IDO expression by APCs. More preferably, the cell surface markers detected using the kit comprise CD123, CD11c or CCR6.

30        The present invention also relies on the discovery that tumor cells that recruit tolerance-inducing APCs to the tumor exhibit increased tolerance. CCR6, a marker highly associated with IDO expression (IDO<sup>+</sup>), is a receptor for the chemokine mip-3 $\alpha$ , a

chemotactic factor for immature dendritic cells (D. Yang, O. M. Howard, Q. Chen, J. J. Oppenheim, *J. Immunol.* **163**: 1737-1741 (1999)). Elevated mip-3 $\alpha$  expression has been seen in certain tumors (Bell, D., *et al.*, *J. Exp. Med.*, **190**: 1417-1426 (1999)). Thus, tolerance-inducing APCs that express receptors for chemoattractant factors secreted by the tumors play 5 a role in the development of tumor-induced tolerance.

Thus, in another aspect, the present invention also comprises a method for assessing the risk of tumor progression in a subject comprising the steps of:

- (a) assaying a sample of tissue from a tumor or tumor draining lymph nodes from a subject for mip-3 $\alpha$  expression; and
- 10 (b) correlating the risk of tumor progression to mip-3 $\alpha$  expression in the tissue sample, wherein mip-3 $\alpha$  expression is positively correlated with an increase in the risk of tumor progression.

In another aspect, the present invention comprises a kit for assessing the relative risk of tumor progression in a subject comprising reagents for detection of relative levels of 15 expression of mip-3 $\alpha$  in a sample of tissue from a tumor or tumor draining lymph node from a subject, wherein the reagents are packaged in at least one individual container.

For example, malignant melanoma is a tumor with well-defined T cell antigens but which nevertheless is not eliminated by the immune system. In tumor specimens comprising both primary and metastatic lesions, a majority show infiltration of IDO $^+$  cells (FIG. 8B). In 20 addition, recruitment of IDO $^+$  dendritic cells is also seen in carcinoma of the breast, lung, colon and pancreas. Accumulation of these cells occurs primarily around the margins of the tumor and infiltrating along the fibrous stoma, or along the vessels in perivascular cuffs and are not a normal constituent of skin or connective tissue.

Tumor-draining lymph nodes may be a critical site for initiation of anti-tumor 25 immune responses (Ochsenbein, A.F., *et al.*, *Nature* **411**: 1058-1064 (2001)). In an analysis of over 300 tumor-draining lymph nodes from 26 patients with malignant melanoma, markedly abnormal accumulation of IDO $^+$  cells is seen (FIG. 8C - E). The IDO $^+$  cells are found to extensively infiltrate the lymphoid regions of the lymph nodes, largely concentrating in the interfollicular and T cell zones. There is also frequent accumulation around blood 30 vessels (FIG. 8D) and accumulation at the interface between lymphoid tissue and tumor metastases or medullary sinuses (FIG. 8E). Normal lymphoid tissue (tonsillectomy specimens with minimal hypertrophy, or lymph node dissections from patients with early-stage node-negative breast cancer) show only scattered IDO $^+$  cells (Fig.8F), and do not display the extensive focal collections and confluent areas of IDO $^+$  cells seen in tumor-

draining nodes. Also, many primary and metastatic tumors contain individual tumor cells (FIG. 8I) or entire localized regions within the tumor that express mip-3 $\alpha$  by immunohistochemistry. Quantitative analysis of mip-3 $\alpha$  mRNA by real-time PCR confirms mip3 $\alpha$  expression in samples of malignant melanoma (M), renal carcinoma (R), and non-  
5 small cell lung cancer (L) (FIG. 9).

Thus, the present invention identifies IDO $^+$  myeloid dendritic cells as a novel immunoregulatory subset of human APCs. The IDO $^+$  dendritic cell population appears to be distinct from the previously described "plasmacytoid" or pre-DC2 dendritic cells (Liu, Y.J., *Cell* 106, 259-262 (2001)). Thus, pre-DC2 express CD123 do not express CD11c, whereas  
10 CD11c is found on essentially all IDO $^+$  cells *in vitro*. In addition, while it is possible that that pre-DC2 cells may express IDO in some situations, the majority of IDO-expressing cells appear to be myeloid-derived.

The present invention differs from previous application of tolerogenic DCs in that: (1) mature DCs which are more effective than immature DCs at suppressing T cells are used; (2)  
15 a relatively pure preparation of tolerogenic cells (*i.e.* expressing IDO) is used, rather than a preparation contaminated by non-tolerogenic (IDO $^{LO}$ ) cells; and (3) APCs of a type other than DCs may be employed, where the non-dendritic APCs are selected based on expression of IDO. Thus, in an embodiment, the isolated tolerogenic APCs comprise mature dendritic cells cultured under conditions optimized to yield a preparation of IDO $^+$  cells or mature cells  
20 enriched for IDO $^+$  cells by selection of IDO $^+$  cells from a mixed population of IDO $^+$ /IDO $^{LO}$  cells. Selection of IDO $^+$  cells may take advantage of differential expression of cell surface antigens by either the IDO $^+$  or the IDO $^{LO}$  cells. Thus, cells may be separated by immunosorting, differential adherence or other methods known in the art

The present invention differs from previous application of immunizing (non-tolerogenic) DCs in that: (a) a relatively pure preparation of non-tolerogenic cells (*i.e.* not expressing immunosuppressive levels of IDO) is used, rather than a preparation contaminated by tolerogenic (IDO $^+$ ) cells; and (2) APCs of a type other than DCs may be employed, where the non-dendritic APCs are selected based on low or negative expression of IDO. Thus, in an embodiment, the isolated non-tolerogenic APCs comprise mature dendritic cells cultured  
25 under conditions optimized to yield a preparation of IDO $^{LO}$  cells, or mature cells enriched for IDO $^{LO}$  cells by selection of IDO $^{LO}$  cells from a mixed population of IDO $^+$ /IDO $^{LO}$  cells. Selection of IDO $^{LO}$  cells may take advantage of differential expression of cell surface antigens by either IDO $^{LO}$  or IDO $^+$  cells. Thus, cells may be separated by immunosorting,

differential adherence or other methods known in the art. In another embodiment, the isolated non-tolerogenic APCs comprise mature non-dendritic APCs cultured under conditions optimized to yield a preparation of IDO<sup>LO</sup> cells, with or without further enrichment by selection of IDO<sup>LO</sup> cells from a mixed population of IDO+/IDO<sup>LO</sup> cells.

5 The present invention teaches that IDO-expressing APCs cells are tolerogenic, and are found in large numbers in tumors and draining lymph nodes. One mechanism contributing to the accumulation of these cells may be tumor-derived mip-3 $\alpha$ . Mip-3 $\alpha$  is the only known ligand for CCR6, and CCR6 appears to selectively associate with the IDO<sup>+</sup> dendritic cell phenotype *in vitro*. The ability to isolate these IDO<sup>+</sup> and IDO<sup>LO</sup> APCs cells *in vitro* provides  
10 a means to use specific subsets of the IDO expressing monocytes as therapeutics to either increase or decrease immunologic tolerance.

### EXAMPLES

15 **EXAMPLE 1 Cell Culture**

Human monocytes and lymphocytes were isolated by leukocytapheresis and counterflow elutriation (D. H. Munn *et al.*, *J. Exp. Med.* **189**, 1363-1372 (1999)). Monocytes (typically >95% purity) were cultured in 100 mm tissue culture petri dishes in RPMI-1640 medium with 10% newborn calf serum (Hyclone) and including penicillin/streptomycin and 20 glutamine. Cultures received either MCSF (200 U/ml, Genetics Institute) on day 0, or GMCSF (50 ng/ml, R&D Systems) + IL4 (50 ng/ml, R&D Systems) on days 0, 2 and 4. For experiments where CCR6 expression was of interest, cultures received a single dose of GMCSF + IL4 (100 ng/ml each) on day 0, with no further supplementation. Loosely adherent dendritic cells (GMCSF+IL4) were harvested by gentle aspiration; adherent 25 macrophages (MCSF) and non-dendritic APCs (GMCSF + IL4) were harvested with EDTA. Other cultures were conducted in serum-free medium (X-vivo 15; BioWhitaker, Walkersville, MD) plus cytokines.

**EXAMPLE 2 Production of Antibodies**

30 All antibodies were obtained commercially except for polyclonal antiserum against human IDO which was manufactured as a work for hire by ZCB Inc., Hopkinton, MA. All commercial antibodies and reagents were from BD Biosciences-Pharmingen (San Jose, CA) unless specified otherwise. For detection of cell surface antigens, DCs were triple-stained

with anti-CD123-biotin (clone 7G3; it was found that clone 9F5 gave suboptimal results with dendritic cells) followed by streptavidin-perCP, plus anti-CD11c-allophycocyanin (clone S-HCL-3) or anti-CCR6-fluorescein (clone 53103.111, R&D systems, Minneapolis, MN). CCR6 results were also confirmed using a second anti-CCR6 antibody (clone 11A9; 5 Pharmingen). For detection of IDO, cells were fixed and permeabilized (Cytofix/Cytoperm), and then stained with rabbit anti-IDO antibody prepared against the peptide followed by polyerythrin-labeled anti-rabbit secondary antibody (Jackson Immunoresearch, West Grove PA) cross-adsorbed against mouse, human and bovine IgG, for multiple labeling). Dendritic cells were gated on forward and side scatter to exclude contaminating lymphocytes and 10 debris.

For preparation of rabbit anti-IDO antibody, the peptide DLIESGQLRERVEKLNMLC (SEQ ID NO: 1) was prepared based on the GenBank sequence of human IDO (M34455) and conjugated to keyhole limpet cyanogen. Rabbits were immunized with conjugated peptide in Freund's adjuvant (all immunization, antibody 15 preparation and affinity purification steps were performed as a work for hire (QCB, Inc., Hopkinton, MA). This peptide gave the best results out of several different sequences screened for their ability to detect human IDO in formalin-fixed paraffin-embedded tissue and by flow cytometry. Validation studies showed that this antibody immunoprecipitated the expected 45kD band from cell lysates, correlated with IDO mRNA and functional enzymatic 20 activity *in vitro*, identified an interferon- $\gamma$ -inducible antigen in two known-positive cell lines (THP-1 and HeLa), and detected an antigen by immunohistochemistry which was specifically localized to cells with known expression of IDO (the syncytiotrophoblast cells of human placenta; Y. Kudo and C. A. Boyd, *Biochem. Biophys. Acta* 1500, 119-124 (2000)). Results 25 were consistent from animal to animal, and from lot to lot of antibody.

25

### EXAMPLE 3 Regulation of IDO Expression During DC Maturation

In humans DCs, maturation has been associated with loss of tolerogenic activity (Dhodapkar, M.V., et al., *J. Exp. Med.*, 193: 233-238 (2001)). The experiments described in FIG. 4 addressed the issue of whether DC maturation down-regulates IDO mediated 30 suppressor activity. Monocyte-derived DCs where cultured for 7 days in X-vivo 15 medium with GMCSF + IL4 (non-adherent cell population, > 95% IDO $^+$ , > 95% CD123 $^+$ ). During the final two days, the cells were either (A) left as immature DCs (no additions); (B) matured using a cytokine cocktail comprising TNF $\alpha$ , IL1 $\beta$ , IL6 and PGE2 (Jonuleit, H.. et al., *Eur. J.*

*Immunol.*, 27: 3135-3142 (1997)); or (C) matured using monocyte-conditioned medium (Reddy, A., *et al.*, *Blood* 90: 3640-3546 (1997)). Each group was harvested and added to 5 x 10<sup>5</sup> allogeneic T cells in V-bottom 96 well microtiter wells in 200 µl medium (10% fetal calf serum in RPMI)). Differing numbers of DCs were added to a fixed number of T cells to 5 produce the T cell to APC ratios shown (thus, the greater number of APCs are on the left of the axis, the lesser numbers on the right). Replicate groups of wells received either 200 µM 1-methyl-(D)-tryptophan (1-MT) (□), or saline control (Δ), to disclose IDO-mediated suppression (defined as the amount of proliferation restored at each T cell: APC ratio by adding 1-MT and shown for one point as an arrow in panel B). After 5 days, T cell 10 proliferation was measured as the incorporation of tritiated thymidine (Munn, D.H. *et al.*, *J. Exp. Med.*, 189: 1363-1372 (1999)).

FIG. 4A shows that higher numbers of immature dendritic cells (lower APC: T cell ratios) were associated with increased IDO mediated suppression (shown as the reduced T cell proliferation at the lower T cell:APC cell ratios, and as enhancement of proliferation 15 when 1-methyl-(D)-tryptophan was added). In FIG. 4B and 4C, the DCs were matured. It can be seen that the mature DCs show greater IDO mediated suppression (with suppression occurring at T cell:APC cell ratios as low as 100:1). Although the mature DCs were highly suppressive due to the presence of IDO, the mature forms actually function better as antigen-presenting cells compared to the immature form, as revealed by the higher T cell proliferation 20 achieved when suppression was prevented by 1-MT (*i.e.* the difference between □ and Δ for each experiment). Thus, mature DCs derived under conditions optimized in accordance with the invention were both more suppressive and more effective as APCs than mature DCs. Both of these attributes are desirable for induction of tolerance.

25 **EXAMPLE 4 Co-expression of IDO with cell surface markers CD123, CC11c and CCR6 in myeloid APCs.**

Expression of IDO in immature monocyte-derived (myeloid) dendritic cells (Dhopakar, M.V., *et al.*, *J. Exp. Med.* 193: 233-238 (2001)) and in immunosuppressive monocyte-derived macrophages (Munn, D.H., *et al.*, *J. Exp. Med.* 189: 1363-1372 (1999)) 30 was analyzed. FIG. 5 shows the expression of IDO and CCR6 by myeloid antigen-presenting cells which express the cell surface antigen CD123 (CD123<sup>+</sup>). Human monocytes were cultured as described above (Example 1) for 7 days with GMCSF + IL4 to produce myeloid dendritic cells (FIG. 5A and 5C), or for 7 days in MCSF to produce macrophages (FIG. 5B) (Munn, D.H., *et al.*, *J. Exp. Med.* 189: 1363-1372 (1999)). Prior to analysis, cells were

treated with interferon- $\gamma$  (IFN $\gamma$ ) for 18 hrs to induce maximal expression of IDO. Harvested cells were triple-stained for CD123, CD11c and IDO. For FIG. 5D, cells were cultured as in Example 1 except in a commercial, FDA-approved serum-free medium formulation (X-vivo 15; BioWhitaker, Waldersville, MD).

5 As shown in FIG. 5A and B, both preparations contained a discrete subset of cells that expressed IDO following interferon- $\gamma$  treatment. Characterization of these IDO $^+$  cells showed that they all expressed the myeloid-lineage marker CD11c, and CD123, wherein >90% of the IDO $^+$  expressed the myeloid-lineage marker CD11c and >99% of the IDO $^+$  cells expressed CD123. To test whether these were truly DCs, additional phenotyping was performed. Cells 10 were matured with TNF $\alpha$  during the last 2 days of culture, in order to upregulate maturation and costimulatory markers, and non-adherent cells were harvested. Following TNF $\alpha$ , all non-adherent cells displayed a veiled/dendritic morphology. Three-color phenotyping showed that the CD123 $^+$ /IDO $^+$  subset of cells were uniformly CD14 $^-$  and CD83 $^+$ , consistent with their identity as dendritic cells; uniformly CD11b $^+$  and BDCA-2 $^-$  (Dzinek, A., et al., *J. Immunol.*, 165: 6037-6046 (2000)) consistent with their myeloid origin, and distinguishing them from 15 plasmacytoid DCs (Grouard, G., et al., *J. Exp. Med.*, 185: 1101-1111 (1997)); and 100% positive for CD80, CD86 and MHC class II (HLA-DR). Under these conditions (bovine serum-based medium) CD11c expression was high on the CD123 $^+$  subset, and was lower and variable on the CD123 $^{LO}$  subset.

20 In addition, when monocytes were cultured under conditions that favored expression of CCR6 (serum-free medium, single-dose GMCSF + IL4), the CD123 $^+$ /IDO $^+$  cells were almost all (>99%) CCR6 $^+$  (Fig. 5C). For experiments where CCR6 expression was of interest, cultures received a single dose of GMCSF + IL4 (100 ng/ml each) on day 0, with no further supplementation. Moreover, within the myeloid dendritic cell population, IDO and CCR6 25 expression were coincident. T and B cells, which also express CCR6, were excluded from analysis by forward and side scatter properties during flow cytometric analysis. The cell surface CCR6 on these cells was functional: when immature dendritic cells containing a mixture of CCR6-positive and -negative cells were placed in chemotaxis chambers, the CCR6-positive cells selectively migrated in response to a mip3 $\alpha$  gradient (data not shown).

30 Expression of IDO is not found in all types of dendritic cells. Analysis of plasmacytoid dendritic cells, defined as the population of peripheral blood mononuclear cells expressing CD123 but negative for lineage-specific markers (Lin-1 marker cocktail, BD-Pharmingen), revealed no detectable expression of IDO following activation for 6 hrs or 24

hrs with interferon- $\gamma$ , in the presence of IL3 to support viability (data not shown). Moreover, when the adherent cells (comprising the non-dendritic APC population) from cultures of peripheral blood mononuclear cells in GMCSF + IL4 were examined, they were found to express very low levels of IDO and little CD123 (FIG. 5D). Additional phenotyping of the 5 non-dendritic APCs showed that they were uniformly CD14-positive and CD83-negative (thus, distinguishing them unambiguously from mature dendritic cells, but were > 95% positive for CD80 and CD86 (thus, identifying them as mature antigen-presenting cells), and expressed high levels of the MHC class II antigen HLA-DR (further distinguishing them from immature dendritic cells, and identifying them as mature APCs). Consistent with the 10 observed absence of IDO expression, these non-dendritic APCs showed excellent APC function without any detectable IDO-mediated suppression (*i.e.* no increase in proliferation in the presence of 1-methyl-(D)-tryptophan (1-MT) (FIG 5E), where stippled bars are standard MLR and striped bars are the MLR with 1-MT. The T cell: APC ratio in FIG 5E was the same (20:1) for both DCs and non-dendritic APCs and both populations were isolated from 15 the same culture of mononuclear cells in GMCSF + IL4 and tested against the same population of T cells in parallel MLRs.

**EXAMPLE 5      Suppression of allogeneic T cell proliferation by dendritic cells expressing IDO.**

20      The experiments shown in the previous example demonstrated that distinct IDO<sup>+</sup> and IDO<sup>LO</sup> subsets can exist in the same preparation of dendritic cells. This example shows that IDO expressing dendritic cells from such a mixture suppress allogeneic T cell proliferation (FIG. 6).

25      Myeloid dendritic cells (derived in bovine serum-based medium as in FIG. 5A) were activated for 24 hrs with TNF $\alpha$  (10 ng/ml, BD), labeled with anti-CD123 antibody, then enriched by sorting with goat anti-mouse secondary antibody conjugated to magnetic beads (Miltenyi Biotec). Since expression of cell-surface CD123 correlated closely with possession of inducible IDO, immunomagnetic sorting based on CD123 was used to enrich for the IDO<sup>+</sup> subset. Cells selected as CD123<sup>+</sup> cells (85-90% purity) by immunomagnetic sorting were 30 then tested as stimulators in an allogeneic MLR. Dot-plots show analysis before ("Presort") and after ("CD123<sup>+</sup>") enrichment (FIG 6A).

    The CD123<sup>+</sup>-enriched cells were used as APCs in an allogeneic MLR. Dendritic cells were mixed with purified allogeneic lymphocytes (<1% monocytes, 80-85% T cells, with the

balance being B and natural killer (NK) cells) at a 1:10 ratio in V-bottom culture wells. After 5 days, proliferation was measured by 4 hr thymidine incorporation assay. Controls shown include the unfractionated population ("Pre-sort") and the cells remaining after positive selection for CD123 ("Depleted"). Typically <10% of the "Depleted" cell population was 5 CD123<sup>+</sup>. Solid bars show conventional MLR; open bars show MLR in the presence of 200 uM 1-methyl-(D,L)-tryptophan (1-MT) (Sigma-Aldrich, St. Louis, MO), an inhibitor of IDO. In a similar set of experiments, 3 different pairs of donors, each allogeneic to the other, and each pair pre-tested to produce an active MLR were used without 1-MT (solid bars) or with 1-MT (open bars) (FIG. 6C).

10 As shown in FIG. 6B and C, the CD123-enriched (CD123<sup>+</sup>) IDO<sup>+</sup> cells were markedly less efficient at stimulating T cell proliferation than either the original unfractionated mixture, or than the CD123-depleted IDO<sup>LO</sup> subset that remained after sorting. To test the hypothesis that this lack of proliferation was due to active suppression by IDO, 15 cultures were treated with 1-methyl-(D,L)-tryptophan (1-MT), a pharmacologic inhibitor of IDO. In the presence of 1-methyl-(D,L)-tryptophan, the CD123<sup>+</sup> dendritic cells stimulated proliferation at or near control levels (FIG. 6B and C), demonstrating that IDO causes suppression.

20 **EXAMPLE 6      Sorting on the basis of cell surface CD123+ results in enrichment of the IDO+ population**

This example shows that sorting dendritic cells to select for CD123<sup>+</sup> cells results in a population of cells which exhibits high levels of IDO expression. In this experiment, 25 monocyte derived dendritic cells (DCs) were labeled with anti-CD123 antibody and using immunomagnetic sorting. Immediately after sorting, cells were dual-stained for CD123 (surface) and IDO (intracellular). As seen in FIG. 7, the positively selected cells were approximately 90% CD123<sup>+</sup>. In addition, all (> 99%) of the cells showed high levels of IDO as detected by staining. In contrast, the residual cells following CD123 depletion were mostly CD123 negative, and expressed low, or undetectable levels of IDO. Thus, it was found that the CD123 depleted population had 10-100 fold lower levels of IDO than the 30 CD123<sup>+</sup> population (FIG. 7).

**EXAMPLE 7      Detection of IDO-expressing CD123<sup>+</sup> dendritic cells in human tumors and draining lymph nodes.**

5      This example shows that CD123<sup>+</sup> dendritic are associated with human tumors and draining lymph nodes. Samples of tumor and tumor-draining lymph nodes were chosen from patients with malignant melanoma, a tumor with well-defined T cell antigens but which nevertheless is not eliminated by the immune system. Recruitment of IDO<sup>+</sup> dendritic cells was also seen in carcinoma of the breast, lung, colon and pancreas, tumors which account for almost half of all cancer deaths in the United States.

10     Archival pathology specimens were stained for expression of IDO and other antigens by immunohistochemistry. Paraffin sections (5 um) were deparaffinized, treated for 8 min with proteinase K (Dako, Carpinteria, CA), and stained with rabbit anti-human IDO antibody (5 µg/ml in Tris buffered saline with 0.05% Tween-20 and 10% goat serum). Detection was via secondary antibody conjugated to alkaline phosphatase (LSAB-rabbit kit, Dako) with Fast 15     Red chromogen, or horseradish peroxidase (LSAB2, Dako) and diaminobenzidine. Negative controls consisted of the anti-IDO antibody neutralized with a 100-fold molar excess of the immunizing peptide. Mip-3 $\alpha$  (goat polyclonal, R&D Systems) was used following antigen retrieval with citrate (Target, Dako). For dual-staining, the first antibody was applied following appropriate antigen retrieval and detected with peroxidase/diaminobenzidine.

20     Stained slides were then subjected to additional antigen retrieval if required and stained for the second antigen by alkaline phosphatase/Fast Red. Secondary antibodies were cross adsorbed against mouse, human and bovine IgG for multiple labeling.

25     In all of these studies, the IDO<sup>+</sup> cells observed appeared to be of the same cell type, displaying a characteristic morphology resembling plasmacytoid DCs (Cella, M., *et al.*, *Nature Medicine* 5: 919-923 (1999)); Grouard, G., *et al.*, *J. Exp. Med.*, 185: 1101-1111 (1997); Facchetti, F., *et al.*, *J. Pathol.*, 158: 57-65 (1989)). They were neither histiocytic (macrophage-like) nor classically dendritic in appearance, and did not mark with Ham56 (a macrophage marker) or S100 (a marker of classical dendritic cells) (data not shown). Shown in FIG 8A is a known positive control for detection of IDO (brown, diaminobenzidine 30     chromogen) in syncytiotrophoblast cells of term human placenta (Kudo, Y., *et al.*, *Biochem. Biophys. Acta* 1500: 119-124 (2000)). The inset shows the same tissue, but with anti-IDO antibody neutralized by an excess of the immunizing peptide. (Bar = 100 um, inset at half-scale).

For normal lymphoid tissue controls, non-inflamed tonsil (from routine tonsillectomy, pathologic diagnosis of "hypertrophy") and lymph nodes from patients with node-negative breast cancer who never developed metastases or recurred in 5 years following resection were used. Although not technically "normal," these specimens were the least inflamed lymphoid tissue removed in routine clinical practice. Over 20 of these specimens have been examined, and they consistently show only rare, scattered IDO<sup>+</sup> cells, usually localized to germinal centers (Fig 8F).

For tumor-draining lymph nodes from regional lymph node dissections in patients with a variety of solid tumors (breast, colon, lung, and pancreatic carcinoma, and malignant melanoma) were used. Most of these nodes were not mapped by lymphoscintigraphy, so not all would actually drain the tumor, but many would. In all 5 types of tumor examined, approximately one-third to one-half of patients had one or more lymph nodes showing markedly abnormal collections of IDO<sup>+</sup> cells (FIG. 8C). In these nodes, often massive infiltrates of IDO<sup>+</sup> cells were localized to the perifollicular and interfollicular areas, often adjacent to the medullary sinuses, or collected in dense perivascular cuffs around high endothelial venules (FIG. 8D). In 328 lymph nodes from 26 patients with melanoma, abnormal infiltration of IDO<sup>+</sup> cells was found in 14/26 patients. Where micro-metastases to lymph nodes were present, IDO<sup>+</sup> cells often surrounded the margins of the tumor collections (Fig. 8E).

Thus, FIG. 8C shows a draining lymph node of a malignant melanoma showing accumulation of IDO-expressing cells (red) in the lymphoid and perivascular regions of the node, but sparing the macrophage-rich sinuses (asterisk). (Bar = 100  $\mu$ m). FIG. 8D shows a higher magnification of panel C, showing a characteristic collection of IDO-expressing cells around a high-endothelial venule (V). (Bar = 50  $\mu$ m). FIG. 8E shows a low-power view of a draining lymph node containing heavily pigmented metastatic melanoma cells (endogenous melanin, black; darkest signal), with confluent infiltration of IDO-expressing cells (red; next darkest signal) around the tumor deposits.

For solid tumors, 14 malignant melanoma tumors were examined with 8/14 found to display collections of IDO<sup>+</sup> cells at the site of the primary tumor. Usually these were in the connective tissue immediately surrounding the tumor (Fig. 8B, arrows) rather than in the tumor parenchyma itself. Similar infiltrates of IDO<sup>+</sup> cells have been seen in breast, lung, and pancreatic tumors.

For inflamed lymphoid tissue tonsils known to be infected (either by clinical diagnosis or by histopathologic diagnosis) and lymph node biopsies bearing the

histopathologic diagnosis of "reactive lymph node" were examined. Many of these specimens showed focal or regional collections of IDO<sup>+</sup> cells. In tonsils these collections frequently occurred in a subepithelial location beneath the mucosa and along the crypts (not shown).

5        Finally, gut-associated lymphoid tissue from the (human) small intestine was examined since IDO<sup>+</sup> DCs derived *in vitro* expressed CCR6, and mice with a targeted disruption of CCR6 (Varona, R., *et al.*, *J. Clin. Invest.*, 107: R37-45 (2001)) fail to recruit a population of myeloid DCs into the lymphoid tissue of the gut. Fig. 6G shows prominent collections of IDO<sup>+</sup> cells in the lamina propria overlying lymphoid aggregates in the gut, 10      congregating near cells expressing mip-3 $\alpha$  (the ligand for CCR6 (Sozzani, S. *et al.*, *J. Leukocyte Biol.* 66: 1-9 (1999); Zlotnik, A., *et al.*, *Immunity* 12: 121-127 (2000)).

10        Thus, it was found that cells expressing IDO (and CCR6) co-localized with cells expressing mip-3 $\alpha$ . Sections of normal human small intestine were used as a positive control for mip-3 $\alpha$  expression, since murine studies have shown that mip-3 $\alpha$  is highly expressed in 15      the subepithelial tissues overlying mucosal lymphoid aggregates of the small intestine (A. Iwasaki and B. L. Kelsall, *J. Exp. Med.* 191: 1381-1394 (2000)). As shown in FIG. 8G, the corresponding region in humans contained focal collections of cells expressing mip-3 $\alpha$ , along 20      with extensive co-localization of IDO-expressing dendritic cells to the same areas. Thus, FIG. 8G and H shows co-localization of cells expressing IDO (brown; darkest cytoplasmic signal) and mip-3 $\alpha$  (red; next darkest cytoplasmic signal) in the lamina propria of the small intestine, particularly in the subepithelial areas overlying mucosal lymphoid aggregates (LA). FIG 8H shows a higher magnification of the region in panel G indicated by the arrow. Bar = 50 um.

25        Examination of mip-3 $\alpha$  expression in malignancies showed that many primary and metastatic tumors contained individual tumor cells (Fig. 8I) or entire localized regions within the tumor that expressed mip-3 $\alpha$  by immunohistochemistry. Although both mip-3 $\alpha$  and IDO expressing cells are found in the tumor, they did not appear to be located in identical cells. Thus, FIG 8I shows expression of mip-3 $\alpha$  (red) (arrow, lower right) by tumor cells in a lesion of malignant melanoma metastatic to lymph node. The mip-3 $\alpha$ <sup>+</sup> cells are scattered 30      throughout the tumor (T), while the IDO<sup>+</sup> cells are congregated at the margins of the metastasis but confined to the residual lymph node tissue (LN). FIG 8J shows a higher magnification of the region in panel M indicated by the arrow, showing mip-3 $\alpha$  expression in tumor cells where the bar = 50 um.

In addition, the morphology of these cells showed that they were tumor cells, not stroma or other host-derived cells. Quantitative analysis of mip-3 $\alpha$  mRNA by real-time PCR confirmed expression in 8/18 samples of malignant melanoma (see Example 8). To ensure that this was not an idiosyncratic property of melanomas, additional RNA samples were 5 analyzed from tumors of unrelated histology and cell of origin (renal cell carcinoma and non-small cell lung cancer). This confirmed that a variety of tumor types express mip-3 $\alpha$  (D. Bell *et al.*, *J. Exp. Med.* 190, 1417-1426 (1999)).

#### EXAMPLE 8      Quantification of mip-3 $\alpha$ expression in human tumors

10      It was found that human tumors express mip-3 $\alpha$ . RNA was isolated from melanomas (M, n=18), renal cell carcinomas (R, n=19) or non-small cell lung cancers (L, n=9) and analyzed for expression of mip-3 $\alpha$  by quantitative RT-PCR (FIG. 9). The RNA was reverse-transcribed using random hexamer priming and analyzed using the LightCycler real-time 15 PCR system (Roche, Indianapolis, IN) and FastStart DNA Amplification Kit (SYBR Green 1, Roche). The primers used were: GAPDH (GenBank GI:7669491, sense basepairs (bp) 87 104, antisense bp 289-307) and mip-3 $\alpha$  (GenBank GI:4759075, sense bp 103-121, antisense bp410-428). Standard curves were prepared from U937 cells induced with phorbol myristate acetate for 24 hrs, and were linear ( $r = -0.99$ ) in the range of 100 pg to 100 ng total RNA.

20      It was found that there was an increase in mip-3 $\alpha$  mRNA in all three tumor types assayed (FIG. 9). To permit comparison between different samples the data are presented as an index, calculated as the ratio of mip-3 $\alpha$  to the GAPDH housekeeping gene in each sample, normalized to the value of the control cell line (resting U937 cells). The data shown thus 25 represent fold increase of mip-3 $\alpha$  expression over that for GAPDH.

The invention has been described in detail with particular reference to preferred 25 embodiments thereof, but it will be understood that variations and modifications can be effected within the spirit and scope of the invention. References cited herein are incorporated in their entirety by reference unless otherwise noted.

CLAIMS

What is claimed is:

5

1. A method of making antigen-presenting cells (APCs) for enhancing T-cell tolerance comprising the steps of:

(a) isolating antigen-presenting cells (APCs) or their precursors (APC progenitors) from a first subject; and

10 (b) treating said isolated cells to select for tolerance-inducing APCs expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity sufficient to suppress proliferation of T cells (IDO<sup>+</sup> APCs).

15 2. The method of claim 1, wherein said tolerance-inducing IDO<sup>+</sup> APCs comprise at least 90% of the APC population expressing IDO at levels of at least 2-fold over background.

3. The method of claim 1, wherein said tolerance-inducing IDO<sup>+</sup> APCs comprise at least 95% of the APC population expressing IDO at levels of at least 2-fold over background.

20 4. The method of claim 1, wherein said tolerance-inducing IDO<sup>+</sup> APCs comprise suppressor activity comprising an at least a 2-fold increase in T cell proliferation in the presence of an IDO inhibitor as compared to in the absence of an IDO inhibitor.

25 5. The method of claim 4, wherein said IDO inhibitor comprises 1-methyl-(D,L)-tryptophan,  $\beta$ -(3-benzofuranyl)-(D,L)-alanine,  $\beta$ -(3-benzo(b)thienyl)-(DL)-alanine, or 6-nitro-(DL)-tryptophan.

6. The method of claim 4, wherein said IDO inhibitor comprises 1-methyl-(D)-tryptophan or 6-nitro-(D)-tryptophan.

30

7. The method of claim 1, wherein said isolated APCs or APC progenitors comprise mature blood-derived dendritic cells, mature tissue dendritic cells, non-dendritic APCs, monocyte-derived macrophages, B cells, plasma cells, or any mixture thereof.

8. The method of claim 1, wherein said isolated APCs or APC progenitors comprise a cell type bearing markers of antigen presentation and costimulatory function.
9. The method of claim 1, wherein said APCs or APC progenitors are isolated from 5 peripheral blood, bone marrow, lymph nodes or a solid organ from a mammal.
10. The method of claim 9, wherein said mammal is a human.
11. The method of claim 1, wherein step (b) comprises culturing said cells in medium 10 which is essentially free of serum.
12. The method of claim 1, wherein step (b) comprises culturing said cells in the presence of macrophage colony stimulating factor (MCSF).
13. The method of claim 1, wherein step (b) comprises culturing said cells in the presence 15 of granulocyte-macrophage colony stimulating factor (GMCSF).
14. The method of claim 1, wherein step (b) comprises culturing said cells in the presence of IL4.
- 20
15. The method of claim 1, wherein step (b) comprises culturing said cells in the presence of TGF $\beta$ .
16. The method of claim 1, wherein step (b) comprises culturing said cells in the 25 presence of IL10.
17. The method of claim 1, wherein step (b) comprises culturing said cells with an agent to cause maturation of said IDO $^+$  APCs.
18. The method of claim 17, wherein said maturation agent comprises TNF $\alpha$ , IL10, 30 TGF $\beta$ , CD40-ligand, activating anti-CD40 antibodies, cells engineered to express cell-surface CD40-ligand, proinflammatory bacterial or pathogen products, or any combination thereof.

19. The method of claim 1, wherein step (b) comprises genetically modifying said APCs or APC progenitors such that the final preparation comprises APCs expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity sufficient to suppress proliferation of T cells (IDO<sup>+</sup> APCs).

5

20. The method of claim 1, wherein step (b) comprises measuring expression of at least one cell surface marker that identifies the APCs as expressing levels of IDO sufficient to suppress proliferation of T cells (IDO<sup>+</sup> APCs) or as expressing levels of IDO not sufficient to suppress proliferation of T cells (IDO<sup>LO</sup> APCs).

10

21. The method of claim 20, wherein said cell surface marker is used to separate said IDO<sup>+</sup> APCs from said IDO<sup>LO</sup> APCs.

15

22. The method of claim 21, wherein said marker comprises CD123, CD11c, CCR6, CD14, or any combination thereof.

20

23. The method of claim 1, further comprising employing differential adhesion to a substrate to separate APCs expressing levels of IDO sufficient to suppress proliferation of T cells (IDO<sup>+</sup> APCs) from APCs expressing levels of IDO not sufficient to suppress proliferation of T cells (IDO<sup>LO</sup> APCs).

24. The method of claim 1, wherein said subject from which said APCs or APC progenitors are isolated comprises a tissue donor to a second subject.

25

25. The method of claim 1, wherein said subject from which said APCs or APC progenitors are isolated comprises a mammal with an autoimmune disorder.

26. The method of claim 1, further comprising exposing the treated APCs of step (b) to at least one source of antigen.

30

27. The method of claim 26, wherein said antigen comprises a natural or synthetic polypeptide.

28. The method of claim 26, where said source of antigen comprises at least one antigen expressed by a donor tissue graft.

29. The method of claim 26, wherein said source of antigen comprises at least one antigen to which the first subject has an autoimmune disorder

5

30. The method of claim 1, further comprising transfecting or genetically engineering said treated APCs of step (b) to express at least one antigenic polypeptide.

10 31. A method for enhancing the number of tolerance-inducing antigen-presenting cells (APCs) in a subject comprising treating said subject to increase the production of APCs or their precursors (APC progenitors) expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity sufficient to suppress proliferation of T cells (IDO<sup>+</sup> APCs).

15 32. A method for enhancing tolerance in a subject comprising the steps of:

(a) isolating antigen-presenting cells (APCs) or their precursors (APC progenitors) from a first subject;

(b) treating said cells to select for tolerance-inducing APCs expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity sufficient to suppress proliferation of T cells (IDO<sup>+</sup> APCs); and

20 (c) administering said treated cells of step (b) to the original subject or to a second subject in an amount effective to generate a tolerance-promoting response in said recipient subject.

25 33. The method of claim 32, wherein said tolerance-promoting response reduces T cell activation in said recipient subject.

34. The method of claim 32, wherein said tolerance-promoting response prolongs the survival of transplanted cells or tissues in said recipient subject.

30 35. The method of claim 32, wherein said tolerance-promoting response reduces the symptoms of an autoimmune disease in said recipient subject.

36. The method of claim 32, wherein said subject from which said APCs or APC progenitors are isolated comprises a tissue donor to the recipient subject.

37. The method of claim 32, wherein said subject from which said APCs or APC progenitors are isolated comprises a mammal with an autoimmune disorder.

38. The method of claim 32, further comprising exposing said treated APCs of step (b) to at least one source of antigen.

39. The method of claim 38, wherein said antigen comprises a synthetic or natural polypeptide.

40. The method of claim 38, where said antigen comprises at least one antigen expressed by a donor tissue graft.

41. The method of claim 38, where said antigen comprises at least one antigen to which said recipient subject has an autoimmune disorder.

42. The method of claim 32, further comprising transfecting or genetically engineering said treated cells of step (b) to express at least one antigenic polypeptide.

43. A composition for enhancing T cell tolerance comprising isolated antigen-presenting cells (APCs) selected as comprising APCs expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity sufficient to suppress proliferation of T cells (IDO<sup>+</sup> APCs).

44. The composition of claim 43, wherein said isolated IDO<sup>+</sup> APCs comprise at least 90% of the APC population expressing IDO at levels of at least 2-fold over background.

45. The composition of claim 43, wherein said isolated IDO<sup>+</sup> APCs comprise at least 95% of the APC population expressing IDO at levels of at least 2-fold over background.

46. The composition of claim 43, wherein said isolated IDO<sup>+</sup> APCs comprise suppressor activity comprising an at least a 2-fold increase in T cell proliferation in the presence of an IDO inhibitor as compared to in the absence of an IDO inhibitor.

47. The composition of claim 43, wherein said isolated IDO<sup>+</sup> APCs express at least one antigenic polypeptide.

5 48. The composition of claim 43, wherein said isolated cells comprise at least one cell surface marker that identifies the cells as expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity sufficient to suppress proliferation of T cells (IDO<sup>+</sup> APCs).

10 49. The composition of claim 48, wherein said marker comprises CD123, CD11c or CCR6.

50. The composition of claim 43, further comprising a pharmaceutically acceptable carrier.

15 51. The composition of claim 43, further comprising one or more immunosuppressive pharmaceuticals in a unit dosage form.

52. An antigen-presenting cell selected as comprising expression of indoleamine 2,3-dioxygenase (IDO) enzyme activity at a level sufficient to suppress proliferation of T cells.

20 53. Antigen-presenting cells comprising expression of indoleamine 2,3-dioxygenase (IDO) enzyme activity at a level sufficient to suppress proliferation of T cells (IDO<sup>+</sup> APCs) made by the method of claim 1.

25 54. A method of making antigen-presenting cells (APCs) for enhancing T-cell dependent immunologic activation in a subject comprising the steps of:

- (a) isolating antigen-presenting cells (APCs) or their precursors (APC progenitors) from a subject; and
- (b) treating said isolated cells to select for APCs expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme not sufficient to cause suppression of T cell proliferation (IDO<sup>LO</sup> APCs).

55. The method of claim 54, wherein said IDO<sup>LO</sup> APCs comprise a population of APCs having less than 10% of the population expressing IDO at a level of greater than 2-fold over background.

5 56. The method of claim 54, wherein said IDO<sup>LO</sup> APCs comprise a population of APCs having less than 5% of the population expressing IDO at a level of greater than 2-fold over background.

10 57. The method of claim 54, wherein said IDO<sup>LO</sup> APCs comprise an absence of suppressor activity comprising less than a 1.5-fold increase in T cell proliferation in the presence of an IDO inhibitor as compared to in the absence of an IDO inhibitor.

15 58. The method of claim 57, wherein said IDO inhibitor comprises 1-methyl-(D,L)-tryptophan,  $\beta$ -(3-benzofurany)-(D,L)-alanine,  $\beta$ -(3-benzo(b)thienyl)-(D,L)-alanine, or 6-nitro-(DL)-tryptophan.

59. The method of claim 57, wherein said IDO inhibitor comprises 1-methyl-(D)-tryptophan or 6-nitro-(D)-tryptophan.

20 60. The method of claim 54, wherein said isolated APCs or APC progenitors comprise mature blood-derived dendritic cells, mature tissue dendritic cells, monocyte-derived macrophages, non-dendritic APCs, B cells, plasma cells, or any mixture thereof.

25 61. The method of claim 54, wherein said isolated APCs or APC progenitors comprise a cell type bearing markers of antigen presentation and costimulatory function.

62. The method of claim 54, wherein said APCs or APC progenitors are isolated from peripheral blood, bone marrow, lymph nodes or a solid organ from a mammal.

30 63. The method of claim 62, wherein said mammal is a human.

64. The method of claim 54, wherein step (b) comprises culturing said cells in the presence of serum-free medium.

65. The method of claim 54, wherein step (b) comprises culturing said cells in the presence of macrophage colony stimulating factor (MCSF).

5 66. The method of claim 54, wherein step (b) comprises culturing said cells in the presence of granulocyte-macrophage colony stimulating factor (GMCSF).

67. The method of claim 54, wherein step (b) comprises culturing said cells in the presence of interferon- $\alpha$ .

10 68. The method of claim 54, wherein step (b) comprises culturing the cells with an agent to cause maturation of said APCs.

15 69. The method of claim 68, wherein said maturation agents comprise TNF $\alpha$ , CD40-ligand, activating anti-CD40 antibodies, cells engineered to express cell-surface CD40-ligand, proinflammatory bacterial or pathogen products, or any combination thereof.

70. The method of claim 54, wherein step (b) comprises culturing said cells in the presence of neutralizing antibodies for IL10.

20 71. The method of claim 54, wherein step (b) comprises culturing said cells in the presence of neutralizing antibodies for TGF $\beta$ .

25 72. The method of claim 54, wherein step (b) comprises genetically modifying the APCs or APC progenitors such that the final preparation comprises APCs expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity not sufficient to suppress proliferation of T cells (IDO $^{LO}$  APCs).

30 73. The method of claim 54, wherein step (b) comprises measuring expression of at least one cell surface marker that identifies the cells as expressing levels of IDO not sufficient to suppress proliferation of T cells (IDO $^{LO}$  APCs) or as expressing levels of IDO sufficient to suppress proliferation of T cells (IDO $^+$  APCs).

74. The method of claim 73, wherein said cell surface marker is used to separate IDO $^{LO}$  APCs from IDO $^+$  APCs.

75. The method of claim 73, wherein said marker comprises CD123, CD11c, CCR6, CD14, or any combination thereof.

5 76. The method of claim 54, wherein step (b) comprises employing differential adhesion to a substrate to separate APCs as expressing levels of IDO not sufficient to suppress proliferation of T cells ( $IDO^{LO}$  APCs) from APCs expressing levels of IDO sufficient to suppress proliferation of T cells ( $IDO^+$  APCs).

10 77. The method of claim 54, further comprising exposing the treated APCs of step (b) to at least one source of antigen.

78. The method of claim 77, wherein said antigen comprises a synthetic or natural polypeptide.

15 79. The method of claim 77, wherein said antigen is expressed by a tumor.

80. The method of claim 77, wherein said antigen is expressed by a pathogen.

20 81. The method of claim 54, further comprising transfecting or genetically engineering the treated APCs of step (b) to express at least one antigenic polypeptide.

25 82. A method for increasing the number of non-suppressive antigen-presenting cells (APCs) in a subject comprising treating said subject to increase the population of APCs or their precursors (APC progenitors) expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity not sufficient to cause suppression of T cell proliferation ( $IDO^{LO}$  APCs).

83. A method for increasing the protective immune response in a subject comprising the steps of:

30 (a) isolating antigen-presenting cells (APCs) or their precursors (APC progenitors) from a first subject;

(b) treating said isolated cells to select for APCs expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity not sufficient to cause suppression of T cell proliferation ( $IDO^{LO}$  APCs); and

(c) administering said treated cells of step (b) back into the subject in an amount effective to generate a protective immune response in said subject.

84. The method of claim 83, wherein a protective immune response comprises a reduction 5 in proliferation of tumor cells or a reduction in the clinical progression of a malignancy.

85. The method of claim 83, wherein a protective response is associated with a reduced pathogen load or increased resistance to at least one pathogen.

10 86. The method of claim 83, further comprising exposing the treated APCs of step (b) to at least one source of antigen.

87. The method of claim 86, wherein said antigen comprises a natural or synthetic 15 polypeptide.

88. The method of claim 86, wherein said antigen is expressed by a tumor.

89. The method of claim 86, wherein said antigen is expressed by a pathogen.

20 90. The method of claim 83, further comprising transfecting or genetically engineering the treated APCs of step (b) to express at least one antigenic polypeptide.

25 91. A composition for increasing T cell activation comprising isolated antigen-presenting cells (APCs) selected as comprising APCs expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity not sufficient to cause suppression of T cell proliferation (IDO<sup>LO</sup>) APCs.

92. The composition of claim 91, wherein said IDO<sup>LO</sup> APCs comprise a population of 30 APCs having less than 10% of the population expressing IDO at a level of greater than 2-fold over background.

93. The composition of claim 91, wherein said IDO<sup>LO</sup> APCs comprise a population of APCs having less than 5% of the population expressing IDO at a level of greater than 2-fold over background.

94. The composition of claim 91, wherein IDO<sup>LO</sup> APCs comprise an absence of suppressor activity comprising less than a 1.5-fold increase in T cell proliferation in the presence of an IDO inhibitor as compared to in the absence of an IDO inhibitor.

5

95. The composition of claim 91, wherein said IDO<sup>LO</sup> APCs comprise at least one cell surface marker that identifies the cells as expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity not sufficient to cause suppression of T cell proliferation (IDO<sup>+</sup> APCs).

10

96. The composition of claim 95, wherein said marker comprises CD14.

97. The composition of claim 95, wherein said marker increases the adhesion of IDO<sup>LO</sup> APCs to plastic.

15

98. The composition of claim 91, further comprising a pharmaceutically acceptable carrier.

20

99. An isolated antigen-presenting cell (APC) selected as comprising levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity not sufficient to cause suppression of T cell proliferation (IDO<sup>LO</sup>).

25

100. Antigen-presenting cells (APCs) comprising levels of indoleamine 2,3-dioxygenase (IDO) enzyme activity not sufficient to cause suppression of T cell proliferation (IDO<sup>+</sup> APCs) made by the method of claim 54.

30

101. A method to determine the number of tolerance-inducing antigen-presenting cells (APCs) in a cell population comprising measuring the number of APCs expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme sufficient to suppress proliferation of T cells (IDO<sup>+</sup> APCs) in said population.

102. A kit for determining the number of tolerance-inducing antigen-presenting cells (IDO<sup>+</sup> APCs) in a cell population comprising reagents to measure levels of indoleamine 2,3

dioxygenase (IDO) enzyme in a population of APCs, wherein said reagents are packaged in at least one individual container.

103. A method quantify the ability of a population of antigen-presenting cells to suppress T 5 cell proliferation comprising measuring the ability of said cell population to increase T cell proliferation in the presence of an IDO inhibitor as compared to in the absence of an IDO inhibitor.

104. A kit for determining the ability of a population of antigen-presenting cells to 10 suppress T cell proliferation comprising an IDO inhibitor packaged in at least one individual container.

105. The kit of claim 104, further comprising individual assay vessels which provide a pre- 15 determined cell density.

106. The kit of claim 104, wherein said assay vessels comprise round-bottomed or V- shaped wells.

107. A method for assessing the relative risk of tumor progression in a subject comprising 20 the steps of:

(a) assaying a sample of tissue from a tumor or tumor draining lymph node from a subject for expression of the enzyme indoleamine 2,3-dioxygenase (IDO); and

(b) correlating the risk of tumor progression to IDO expression in said tissue sample, wherein IDO expression is positively correlated with an increase in the risk of tumor 25 progression.

108. The method of claim 107, further comprising identification of cell surface or immunohistochemical markers associated APCs expressing levels of indoleamine 2,3- dioxygenase (IDO) enzyme sufficient to suppress proliferation of T cells (IDO<sup>+</sup> APCs).

109. The method of claim 107, wherein said cell surface markers comprise CD123, CD11c 30 or CCR6.

110. A method for assessing the risk of tumor progression in a subject comprising the steps of:

(a) assaying a sample of tissue from a tumor or tumor draining lymph nodes from a subject mip-3 $\alpha$  expression; and

(b) correlating the risk of tumor progression to mip-3 $\alpha$  expression in said tissue sample, wherein mip-3 $\alpha$  expression is positively correlated with an increase in the risk of tumor progression.

5 111. A kit for assessing the relative risk of tumor progression in a subject comprising reagents for detection of the enzyme indoleamine 2,3-dioxygenase (IDO) in a sample of tissue from a tumor or tumor draining lymph node from a subject, wherein said reagents are 10 packaged in at least one individual container.

112. The kit of claim 111, further comprising reagents for detection of cell surface or immunohistochemical markers associated with antigen-presenting cells (APCs) expressing levels of indoleamine 2,3-dioxygenase (IDO) enzyme sufficient to suppress proliferation of T 15 cells (IDO $^+$  APCs) in said population.

113. The kit of claim 112, wherein said markers comprise CD123, CD11c or CCR6.

114. A kit for assessing the relative risk of tumor progression in a subject comprising 20 reagents for detection of relative levels of expression of mip-3 $\alpha$  in a sample of tissue from a tumor or tumor draining lymph node from a subject, wherein said reagents are packaged in at least one individual container.

1/9




FIG. 1

2/9




FIG. 2

3/9




FIG. 3

4/9





FIG. 4

**FIG. 5**

6/9






FIG. 6

7/9

**Positively-selected (CD123+) DCs****Negatively selected (post-sort, CD123-depleted) DCs****FIG. 7**

8/9





FIG. 8

9/9

**FIG. 9**

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/11319

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 5/00, 5/02; G01N 33/53; A61K 45/00, 47/00; A01N 63/00, 65/00  
 US CL : 435/325, 375, 7.1, 808, 813; 424/278.1, 93.71

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
 U.S. : 435/325, 375, 7.1, 808; 813; 424/278.1, 93.71

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
 WEST, MEDLINE, CAPLUS, BIOSIS, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US2001/0001040 A1 (MUNN et al.) 10 May 2001 (10.05.01), see entire document.	1-114
Y	MUNN, D.H. et al, Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism. J. Exp. Med. 03 May 1999, Vol. 189, No. 9, pages 1363-1372, see entire document.	1-114
Y	HWU, P. et al, Indoleamine 2,3-Dioxygenase Production by Human Dendritic Cells Results in the Inhibition of T Cell Proliferation. J. Immunol. 2000, Vol. 164, pages 3596-3599, see entire document.	1-114
Y	FALLARINO, F. et al, Functional expression of indoleamine 2,3-dioxygenase by murine CD8alpha+ dendritic cells. Int. Immunol. 2002, Vol. 14, No. 1, pages 65-68, see entire document.	1-114
Y	ALEXANDER, A.M. et al, Indoleamine 2,3-Dioxygenase Expression in Transplanted NOD Islets Prolongs Graft Survival After Adoptive Transfer of Diabetogenic Splenocytes. Diabetes. February 2002, Vol. 51, pages 356-365, see entire document.	1-114

<input type="checkbox"/>	Further documents are listed in the continuation of Box C.	<input type="checkbox"/>	See patent family annex.
•	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier application or patent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search	Date of mailing of the international search report
23 July 2002 (23.07.2002)	06 SEP 2002
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230	Authorized officer <i>Valerie J. Bell-Harris Jr.</i> G. R. Ewoldt Telephone No. 703-308-0196